Head-mounted augmented reality near eye display device

Information

  • Patent Grant
  • 12069233
  • Patent Number
    12,069,233
  • Date Filed
    Friday, August 4, 2023
    a year ago
  • Date Issued
    Tuesday, August 20, 2024
    2 months ago
Abstract
Disclosed herein is a near eye assembly having a retaining structure (e.g., a spectacle frame or head up display mounted on a helmet) that is configured to be positioned in proximity to the eye of a user of the assembly. An optical combiner may be mounted on the retaining structure in front of the user eye. The optical combiner may at least partially transmit elements of a scene in front of the assembly through the combiner. In addition, the optical combiner may receive a visible radiation transmission derived from a scene, and/or a visual transmission such as a presentation of data or a marker, and redirect the transmission back to the user's eye.
Description
FIELD OF THE INVENTION

The present invention relates generally to a near eye display system, and specifically to a display able to combine video-based and optic-based augmented reality.


BACKGROUND OF THE INVENTION

A near eye display system may be used in an augmented reality situation, where a scene that is being viewed by a user of the assembly is altered, typically by being augmented or supplemented. The alteration is computer processor generated, and typically involves presenting real time video, and/or non-real time images, to the user while the user is gazing at the scene.


U. S. Patent Application 2010/0149073, to Chaum et al., whose disclosure is incorporated herein by reference, describes a near eye display system. The system includes a source of modulated light, and a “proximal optic” positionable adjacent to an eye of a system user to receive the modulated light. The proximal optic has a plurality of groups of optically redirecting regions.


U. S. Patent Application 2012/0068913, to Bar-Zeev et al., whose disclosure is incorporated herein by reference, describes an optical see-through head-mounted display device. The device includes a see-through lens which combines an augmented reality image with light from a real-world scene, while an opacity filter is used to selectively block portions of the real-world scene so that the augmented reality image appears more distinctly.


U. S. Patent Application 2013/0050258, to Liu et al., whose disclosure is incorporated herein by reference, describes a see-through head-mounted display device that provides an augmented reality image which is associated with a real-world object. Initially, the object is identified by a user, e.g., based on the user gazing at the object for a period of time, making a gesture such as pointing at the object and/or providing a verbal command.


w


SUMMARY OF THE INVENTION

An embodiment of the present invention provides apparatus, including:

    • a retaining structure, configured to be positioned in proximity to an eye of a subject, the eye of the subject having a pupil with a pupil diameter;
    • an optical combiner mounted on the structure in front of the eye;
    • a pixelated screen, having an array of variably transparent pixels, coating the optical combiner;
    • at least one image capturing device mounted on the structure configured to capture an image of a scene viewed by the eye;
    • a projector mounted on the structure and configured to project at least one of a portion of the captured image and a stored image onto a section of the screen at a selected location thereof; and
    • a processor, configured to render the section of the screen at least partially opaque, to select the location of the section in response to a region of interest in the scene identified by analysis of the captured image, and to determine a dimension of the section in response to the pupil diameter.


The processor may be configured to identify the region of interest in response to radiation received by the image capturing device from at least one marker located at the region of interest.


The apparatus may include a further image capturing device configured to identify the region of interest in response to received radiation from at least one marker located at the region of interest. The at least one image capturing device may be configured to operate in the visible spectrum, and the further image capturing device may be configured to operate in the non-visible spectrum. The apparatus may include a radiator configured to radiate radiation in the non-visible spectrum towards the region of interest.


In a disclosed embodiment the apparatus includes at least one marker positioned in proximity to the region of interest, and wherein the processor is configured to detect the marker in the captured image so as to identify the region of interest.


In a further disclosed embodiment the processor is configured to determine an initial pupil diameter in response to the dimension of the section being set by the subject to occlude an object of known size while the subject gazes at the object in a known ambient light brightness. Typically, the processor is configured to determine a brightness of the scene in response to the captured image of the scene, and the processor is configured to determine the pupil diameter in response to the initial pupil diameter and the brightness of the scene.


In a yet further disclosed embodiment the processor is configured to determine an initial pupil diameter in response to analysis of a reflected image of the subject while the subject gazes into a mirror in a known ambient light brightness. Typically, the processor is configured to determine a brightness of the scene in response to the captured image of the scene, and the processor is configured to determine the pupil diameter in response to the initial pupil diameter and the brightness of the scene.


In an alternative embodiment the dimension of the section is determined so that the region of interest is occluded. Typically, a region surrounding the region of interest is partially occluded. A fraction of occlusion in the region surrounding the region of interest may be determined in response to the pupil diameter. The processor may be configured to derive from the captured image an image corresponding to the region surrounding the region of interest, and the projector may be configured to project the derived image onto an area of the screen surrounding the at least partially opaque section of the screen. An intensity of the projected derived image may be determined in response to the fraction of occlusion.


In a further alternative embodiment the dimension of the section is determined in response to a size of the region of interest.


The dimension of the section may be determined so that an area greater than the region of interest is occluded. Alternatively, the dimension of the section may be determined so that an area less than the region of interest is occluded.


In a yet further alternative embodiment the retaining structure is a spectacle frame. Alternatively, the retaining structure is a helmet having a head-up display.


Typically, the at least one image capturing device includes two image capturing devices capturing respective images of the scene, and the processor is configured to identify the region of interest by analysis of the respective images.


There is further provided, according to an embodiment of the present invention, a method, including:

    • positioning a retaining structure in proximity to an eye of a subject, the eye of the subject having a pupil with a pupil diameter;
    • mounting an optical combiner on the structure in front of the eye;
    • coating the optical combiner with a pixelated screen, having an array of variably transparent pixels;
    • mounting at least one image capturing device on the structure so as to capture an image of a scene viewed by the eye;
    • mounting a projector on the structure the projector being configured to project at least one of a portion of the captured image and a stored image onto a section of the screen at a selected location thereof;
    • rendering the section of the screen at least partially opaque;
    • selecting the location of the section in response to a region of interest in the scene identified by analysis of the captured image; and
    • determining a dimension of the section in response to the pupil diameter.


There is further provided, according to an embodiment of the present invention, apparatus, including:

    • a retaining structure, configured to be positioned in proximity to an eye of a subject;
    • an optical combiner mounted on the structure in front of the eye;
    • a pixelated screen, having an array of variably transparent pixels, coating the optical combiner;
    • at least one image capturing device mounted on the structure configured to capture an image of a scene viewed by the eye;
    • a processor, configured to render a section of the screen at least partially opaque, and
    • a projector mounted on the structure and configured to project at least one of a portion of the captured image and a stored image onto the section of the screen so that there is misalignment between the scene viewed by the eye through the combiner and the at least one portion of the captured image and the stored image.


Typically, for a scene at 50 cm from the eye, the misalignment is no more than 2 cm.


The projector may be configured to project the portion of the captured image and the stored image, in registration with each other, onto the section of the screen.


There is further provided, according to an embodiment of the present invention, apparatus, including:

    • a retaining structure, configured to be positioned in proximity to an eye of a subject;
    • an optical combiner mounted on the structure in front of the eye;
    • a rotator connected to the optical combiner and configured to rotate the optical combiner about an axis;
    • a pixelated screen, having an array of variably transparent pixels, coating the optical combiner;
    • at least one image capturing device mounted on the structure configured to capture an image of a scene viewed by the eye; and
    • a processor, configured to render a section of the screen at least partially opaque, and to activate the rotator so that the optical combiner is oriented to be orthogonal to a region of interest in the scene.


The processor is typically configured to select the section of the screen so as to occlude the region of interest.


The axis may be a vertical axis.


There is further provided, according to an embodiment of the present invention, a method, including:

    • positioning a retaining structure in proximity to an eye of a subject;
    • mounting an optical combiner on the structure in front of the eye;
    • coating the optical combiner with a pixelated screen comprising an array of variably transparent pixels;
    • mounting at least one image capturing device on the structure, the device being configured to capture an image of a scene viewed by the eye;
    • rendering a section of the screen at least partially opaque;
    • mounting a projector on the structure; and
    • configuring the projector to project at least one of a portion of the captured image and a stored image onto the section of the screen so that there is misalignment between the scene viewed by the eye through the combiner and the at least one portion of the captured image and the stored image.


There is further provided, according to an embodiment of the present invention, a method, including:

    • positioning a retaining structure in proximity to an eye of a subject;
    • mounting an optical combiner on the structure in front of the eye;
    • connecting a rotator to the optical combiner, the rotator being configured to rotate the optical combiner about an axis;
    • coating the optical combiner with a pixelated screen having an array of variably transparent pixels;
    • mounting at least one image capturing device on the structure, the device being configured to capture an image of a scene viewed by the eye;
    • rendering a section of the screen at least partially opaque; and
    • activating the rotator so that the optical combiner is oriented to be orthogonal to a region of interest in the scene.


The present disclosure will be more fully understood from the following detailed description of the embodiments thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 schematically illustrates use of an augmented reality system, according to an embodiment of the present invention;



FIGS. 2A-2E are schematic diagrams illustrating an augmented reality assembly, as well as functions that may be implemented in the assembly, according to an embodiment of the present invention;



FIGS. 3A, 3B, and 3C are schematic diagrams illustrating the assembly in different orientations with respect to a region of interest, and FIGS. 3D and 3E are graphs derived from the different orientations, according to an embodiment of the present invention;



FIG. 4 is a schematic diagram illustrating derivation of the dimensions of an occlusion mask, according to an embodiment of the present invention;



FIG. 5 is a schematic diagram illustrating partial occlusion of an area around the region of interest, according to an embodiment of the present invention;



FIG. 6 illustrates an occlusion mask, according to an embodiment of the present invention;



FIG. 7 illustrates graphs of occlusion vs. distance, according to an embodiment of the present invention; and



FIG. 8 is a flowchart of steps performed in operation of the augmented reality system, according to an embodiment of the present invention.





DETAILED DESCRIPTION OF EMBODIMENTS
Overview

An embodiment of the present invention provides a near eye assembly having a retaining structure that is configured to be positioned in proximity to the eye of a user of the assembly. Typically, the retaining structure comprises a spectacle frame. Alternatively, the retaining structure comprises a head up-display which may be mounted on a helmet worn by the assembly user.


An optical combiner is mounted on the structure in front of the user eye. Typically, two combiners are mounted, one in front of each eye. The optical combiner at least partially transmits elements of a scene in front of the assembly through the combiner. In addition, the optical combiner may receive a visible radiation transmission derived from a scene, and/or a visual transmission such as a presentation of data or a marker, and redirects the transmission back to the user's eye.


A pixelated screen, comprising an array of variably transparent pixels, coats the optical combiner. Typically, the pixels are liquid crystal display (LCD) pixels.


There is at least one image capturing device, typically two such devices, one for each eye, mounted on the structure. The capturing device is typically a visible spectrum camera that is configured to capture an image of a scene viewed by the user's eye.


A projector, typically a micro-projector, is mounted on the structure. Typically two projectors, one for each eye, are mounted on the structure. The projector is configured to project at least one of a portion of the captured image as a video, as well as a stored image, onto a section of the screen that a processor renders at least partially opaque. The at least partially opaque section is also referred to herein as an occlusion mask, or just as a mask.


The processor is configured to select the location of the section in response to a region of interest in the scene identified by analysis of the captured image. Typically, at least one marker is positioned near the region of interest, and the processor analyzes the captured image to locate the marker and so identify the region of interest. Rendering the section opaque occludes the region of interest from the user's eye.


In addition, the processor determines a dimension of the section, typically, in the case of the section being circular, the diameter of the section. The dimension is determined in response to the pupil diameter.


By setting the dimension of the section according to the pupil diameter, embodiments of the present invention more exactly control the area of the region of interest that is occluded. In addition, because of the finite size of the pupil, there is a region surrounding region of interest that is partially occluded. In some embodiments the processor operates the micro-projector to overlay relevant portions of the captured image on the partially occluded region, so as to compensate for the partial occlusion.


As stated above, a portion of the captured image may be projected as a video onto the occlusion mask. In some embodiments the captured image portion video corresponds to the occluded region of interest. There is a non-occluded region surrounding the occluded region of interest, and this non-occluded region is visible to the user through the combiner. In embodiments of the invention the video and the visible non-occluded region are typically not in accurate registration, due to slight inevitable movements of the display relative to the user's eye.


In some embodiments a stored image, such as an image of a tool, is overlaid on, and in accurate registration with, the occluded region video.


The inventors have found that registering the stored image with the video, even though the video is not fully registered with the surrounding visible region, provides an acceptable image for the user. The inventors have found that for a non-occluded region that appears to be 50 cm from the user's eye, the video and the non-occluded region may be out of registration by up to 2 cm, while still being acceptable to the user.


Thus, in contrast to prior art augmented reality systems, embodiments of the present invention are configured to operate with mis-alignment between the visible portion of a scene and an augmented reality portion of the scene. However, there is no mis-alignment between elements within the augmented reality video, i.e., the elements projected onto the occlusion mask.


In some embodiments, the optical combiner may be rotated about an axis by the processor. In the case of two combiners, they may be independently rotated about respective axes. The independent rotations may be used to orient both combiners so that each is orthogonal to the direction of gaze of the user's eyes.


System Description

Reference is now made to FIG. 1, which schematically illustrates use of an augmented reality system 20, according to an embodiment of the present invention. By way of example and for simplicity, in the following description system 20 is assumed to be used in a medical procedure during part of which the user of the system is being mentored. However, it will be understood that embodiments of the present invention may be used in non-medical and/or non-mentoring situations, such as in operating a video game, in simulating a real-world event, or in providing an aid to navigation.


System 20 is operated by a medical professional 22, who wears an augmented reality assembly 24, described in more detail below with respect to FIGS. 2A-2D. While assembly 24 may be incorporated for wearing into a number of different retaining structures on professional 22, in the present description the retaining structure is assumed to be similar to a pair of spectacles. Those having ordinary skill in the augmented reality art will be aware of other possible structures, such as incorporation of the augmented reality assembly into a head-up display that is integrated into a helmet worn by the user of system 20, and all such structures are assumed to be comprised within the scope of the present invention.


System 20 comprises and is under overall control of a processor 26. In one embodiment processor 26 is assumed to be incorporated within a stand-alone computer 28, and the processor typically communicates with other elements of the system, including assembly 24, wirelessly, as is illustrated in FIG. 1. Alternatively or additionally, processor 26 may use optical and/or conducting cables for communication. In further alternative embodiments processor 26 is integrated within assembly 24, or in the mounting of the assembly. Processor 26 is typically able to access a database 40, wherein are stored images and other visual elements used by system 20. Software enabling processor 26 to operate system 20 may be downloaded to the processor in electronic form, over a network, for example. Alternatively or additionally, the software may be provided on non-transitory tangible media, such as optical, magnetic, or electronic storage media.


The medical procedure exemplified here is on a patient 30, and during the procedure professional 22 gazes along gaze directions 32 at a region of interest (ROI) 34. ROI 34 typically, but not necessarily, comprises a portion of the patient. In some embodiments one or more ROI acquisition markers 35, comprising marker elements 36, are positioned in, and/or in proximity to, ROI 34, and the functions of such markers are described below. Typically there are at least three marker elements 36 for a given marker 35. In a disclosed embodiment the size of ROI 34 may be predefined by professional 22, for example based on a computerized tomography (CT) image of the patient, and the position of the ROI may also be a predefined distance to the right and a predefined distance below the marker. In an alternative embodiment marker elements 36 of marker define ROI 34 to be a region within a surface having elements 36 in the perimeter of the surface. Typically, a margin in an approximate range of 1-5 cm is added to ROI 34 to compensate for mis-alignment between a video projection and a directly viewed scene, described in more detail below.


During the procedure professional 22 may use a surgical device 38, such as a surgical knife, to perform part of the procedure. Typically device 38 comprises one or more identifying elements 39 which may be used to track the device.



FIGS. 2A-2E are schematic diagrams illustrating assembly 24, as well as functions that may be implemented in the assembly, according to an embodiment of the present invention. FIG. 2A illustrates assembly 24 with none of the active elements of the assembly, i.e., those elements requiring power, operating. As stated above, assembly 24 is configured, by way of example, as a pair of spectacles 50. Similar elements of each “half” of the pair of spectacles are referred to generically by an identifying numeral, and the similar elements are differentiated as necessary by adding a letter to the numeral.


Thus spectacles 50 comprise planar optical combiners 52, comprising combiners 52A and 52B in front of, respectively, the left and right eyes of professional 22. Optical combiners 52 are mounted on a retaining structure 54 which holds elements of assembly 24, and which is herein assumed to comprise a spectacle frame, so that structure 54 is also referred to herein as frame 54.


In some embodiments, combiner frames 82A and 82B are fixed to retaining structure 54 and vertical retaining rods 84A and 84B attached to the combiner frames support the optical combiners, so that the combiners are able to rotate about vertical axes defined by the rods. Retaining rods 84A and 84B, and thus combiners 52A and 52B, may be rotated independently of each other about their vertical axes by respective motors 86A and 86B, fixed to frames 82A and 82B. Motors 86, typically stepper motors, are controlled by processor 26 so as to rotate their attached combiners to known, typically different, fixed orientations with respect to their respective combiner frames.


Each optical combiner 52 is configured to at least partially transmit elements of a scene through the combiner, so that a portion 56 of patient 30 (FIG. 1) is assumed to be directly visible through each combiner 52. In addition, each optical combiner 52 is configured to receive a visible radiation transmission derived from a scene, and/or a visual transmission such as a presentation of data or a marker, and to redirect or reflect the transmission back to the eye of professional 22. The redirection is such that the scene and/or data or marker presented to the professional appears to be at a distance between the near and far points of vision of the professional. Thus, any given section of the optical combiner may combine directly visible material with redirected or reflected material, and provide this combined material to the eye of the user. More detail of the functioning of combiners 52 is provided below.


Optical combiners of various types are known in the art. One known type uses a semi reflective surface which transmits an image from an image source after it has passed through a set of lenses which correct deformations caused by the semi reflective surface of the combiner. Another known type uses a waveguide which projects the image directly to the eye of the viewer. Herein, by way of example, combiners 52 are assumed to be of the waveguide type.


In one embodiment, combiners 52 comprise LUMUS DK 32 see through glasses, produced by Lumus Optical of Rechovot, Israel.


Generally similar pixelated variable transparency screens 60A and 60B respectively coat a rear side, i.e., the side away from the eyes of professional 22, of combiners 52A, 52B. Screens 60 are active elements of system 20 and are formed of an array of pixels, the opacity of each of the pixels being controlled by processor 26.


Screens 60 are typically, but not necessarily, liquid crystal displays (LCDs) formed of a rectangular array of liquid crystal pixels. Alternatively, screens 60 are formed of MEMS (microelectromechanical systems). Further alternatively, screens 60 are formed of polymer dispersed liquid crystals (PDLCs). In the following description, by way of example, screens 60 are assumed to be formed of LCDs. LCD display pixels can typically be switched between an opaque state, where approximately 95% of the incoming light is blocked and 5% is transmitted, and a transparent state where approximately 60% of the incoming light is blocked and 40% is transmitted. The LCDs then have a transmission contrast ratio of 1:8.


Fixedly attached to arms of frame 54 are generally similar micro-projectors 64A and 64B. Each micro-projector is located and oriented so as to be able to project onto respective combiner 52A and 52B, a scene, and/or a visual indication, in a form suitable for redirection by the combiners to the left or right eye of professional 22. Micro-projectors 64 are active elements, and the projected scenes/indications are provided to the micro-projectors by processor 26. The projection and redirection are configured so that the images seen by the eyes of professional 22, absent any correcting lenses, appear to be at infinity, due to parallel light coming from the combiners and entering the pupils. In some embodiments display 24 comprises correcting lenses 88A, 88B which redirect light from combiners 52A, 52B so that the images appear to be closer than infinity to the professional's eyes. The power D in diopters of the lenses defines the distance d of the images, according to the formula d=1/D, where d is in meters, and D is a negative number. Lenses 88A, 88B are typically located between the professional's eyes and the respective combiners. For simplicity, lenses 88A, 88B are not shown in other figures of the present application.


At least one image capturing device 68 is attached to frame 54. In the disclosed embodiment there are two generally similar devices 68A and 68B, respectively aligned to be approximately orthogonal to planar combiners 52A and 52B, so as to be able to capture radiation of respective images of scenes viewed by the left and right eyes of professional 22. Typically, devices 68 comprise cameras configured to capture images of scenes in the visible spectrum. The cameras may use rolling shutters, in which cases latency (of projection via micro-projectors 64) may be reduced by processing rows of images rather than complete frames of images. In some embodiments devices 68 may also capture non-visible portions of images, such as portions in the infra-red spectrum. The operation of devices 68 is controlled by processor 26.


In some embodiments of the present invention, assembly 24 comprises a sensor 72 which is configured to capture non-visible images of elements of a scene in front of assembly 24. Typically sensor 72 uses a projector 73 configured to project radiation in the non-visible spectrum detected by the sensor, and has a bandpass filter configured to block visible radiation, such as that projected by surgical lighting. Typically, sensor 72 and projector 73 operate in the near infra-red spectrum.


In some embodiments, assembly 24 comprises a manual and/or electronic control 74 which may be operated by professional 22 to move elements of the assembly in and out of the field of view of the professional. Additionally or alternatively, there may be a button or switch 78 which enables the professional to power active elements of assembly 24, such as the capturing devices and the micro-projectors. In some embodiments switch 78 may be a foot switch. Further additionally or alternatively, assembly 24 may be configured so that it can tilt downwards about a horizontal axis, at an angle up to 40° from the horizontal, so that the professional can look through the assembly when looking down.


Additionally, assembly 24 may comprise a sensor 76, such as an accelerometer, which is configured to measure an inclination of the assembly with respect to the direction of gravity, so measuring the angle of the head of the professional with respect to the vertical. Processor 26 may be configured to use readings from sensor 76 to move elements of assembly 24 in and out of the field of view of the professional, and/or to control whether micro-projectors 64 project images.



FIG. 2B schematically illustrates the appearance of assembly 24 when processor 26 activates screens 60A and 60B. As described above, each screen 60 comprises an array of pixels, and the opacity of each pixel in an individual screen may be set by processor 26. In screen 60A the processor has rendered a circular array 80A of the pixels of the screen opaque, while the remaining pixels of the screen are rendered transparent. The opacity of array 80A means that from the point of view of the left eye of professional 22, circular array 80A acts as a mask occluding corresponding features of portion 56 of the patient, so that array 80A is also referred to herein as occluding mask 80A.


Similarly in screen 60B processor 26 has rendered a circular array 80B of the pixels of the screen opaque, while the remaining pixels of the screen are rendered transparent. As for array 80A, array 80B occludes sections of portion 56 from the view of the right eye of professional 22. Thus array 80B is also referred to herein as occluding mask 80B.



FIG. 2C schematically illustrates the appearance of assembly 24 when processor 26 activates screens 60 and micro-projectors 64A and 64B. Screens 60 are activated to provide occluding masks 80A and 80B, as described above with respect to FIG. 2B. Micro-projector 64A projects a prerecorded ultrasound image 90A of the patient's abdomen so as to overlay the image on mask 80A, and micro-projector 64B projects an image 90B of the abdomen so as to overlay it on mask 80B. Typically, although not necessarily, images 90A and 90B are the same. In some cases, for example if the images have been acquired in a stereoscopic manner or for correct 3D perception, images 90A and 90B may be slightly different, typically being slightly displaced horizontally with respect to each other. Micro-projectors 64 are configured to position images 90A and on their respective masks so that, as seen by professional 22 and with −2 diopter lenses 88A, 88B present, the images are in focus at approximately 50 cm and appear to be at the location of the patient's abdomen.


In addition to projecting images 90, micro-projectors 64 also project alphanumeric data 92A and 92B onto the non-occluded region of screens 60, as well as markers 96A and 96B onto masks 80A and 80B. Images 90, data 92, and markers 96 are typically stored in database 40, and are provided from the database to micro-projectors 64 by processor 26.


In a mentoring situation images 90, the contents of data 92, and the position of markers 96 are typically under control of a tutor interacting with processor 26 while mentoring professional 22. In some cases the locations of masks 80 may also be provided to processor 26 by the tutor, although typically the locations of the masks depend upon gaze directions 32 of the professional. In a non-mentoring situation, i.e. where professional 22 alone operates system 20, locations of masks 80 are typically automatically set by processor 26, as is described below. Also in a non-mentoring situation, images 90, data 92, and markers 96 may be controlled by professional 22. It will be understood that images 90, data 92 and markers 96 are examples of non-video related visual elements that are seen by professional 22, and that the provision of such elements corresponds to an optic-based augmented reality situation implemented in system 20.



FIG. 2D schematically illustrates the appearance of assembly 24 when processor 26 activates screens 60 and micro-projectors 64, and in addition incorporates a video-based augmented reality feature into the operation of the assembly. Screens 60 and micro-projectors 64 are assumed to be activated as described above for FIG. 2C, so that masks 80, images 90, data 92 and markers 96 are in the field of view of professional 22. By way of example, the figure has been drawn to illustrate a mentoring situation, where the tutor of professional 22 wants to point to a feature of the chest of patient 30, herein assumed to comprise an unusual movement of the chest.


To point to the feature, the tutor interacts with processor 26 so that the processor enhances and emphasizes portions 100A, 100B of the video images acquired by capturing devices 68, the portions corresponding to the region of the chest where the unusual movement is occurring. Micro-projectors 64A, 64B then project portions 100A, 100B onto combiners 52A, 52B. It will be understood that the enhancement of portions 100A, 100B and their projection on the respective combiners is in real-time. The enhancement may take a number of forms. For example, portions 100A, 100B may comprise a wireframe image of the region of the chest having unusual movement, and/or a false-color image of the region. Other suitable methods of real-time enhancement will be apparent to those having ordinary skill in the art, and all such methods are assumed to be within the scope of the present invention.



FIG. 2E schematically illustrates an overall scene 101 as seen by professional 22, during an invasive surgical procedure being performed by the professional. For simplicity, FIG. 2E illustrates the scene as it is presented on combiner 52A, and it will be understood that a substantially similar scene is presented to the professional on combiner 52B. The figure illustrates a hand 102 of professional 22 holding device 38, herein assumed to comprise a pair of tweezers, at a proximal end of the device. One or more device identifying elements 39, typically reflectors and/or radiators, are attached to the tweezers, so that processor 26 is able to identify and track device 38 using images acquired by capturing devices 68.


The professional has made an incision 104 in a portion 106 of patient 30, and ROI 34, defined by marker elements 36, is assumed to be at the location of the incision. In addition, the professional has inserted a lower portion of the distal end of device 38 into the patient so that the lower portion is no longer visible.


Processor 26 has formed mask 80A on combiner 52A so as to occlude ROI 34, and the portion of incision 104 comprised in the ROI. Mask 80A also includes a margin 83, typically corresponding to a margin of approximately 1-5 cm at the ROI. Thus, all elements of the scene outside mask 80A, comprising hand 102 and the proximal end of device 38, are directly visible through combiner 52A by the professional. However, elements of the scene within mask 80A, including a portion of incision 104 and an upper portion of the distal end of device 38 that is outside the patient, are not visible to the professional, since they are occluded by the mask.


Processor 26 overlays on mask 80A a captured image 110 of the ROI and the region corresponding to margin 83, which includes the portion of incision 104 occluded by the mask and which also includes a video image 114 of the upper portion of the distal end of device 38 (outside the patient) that has been captured by image capturing device 68. In addition, the processor overlays on the occlusion mask a stored image 112 corresponding to the lower portion of the distal end of device 38 (within the patient). Stored image 112 is a virtual elongation of image 114 and is retrieved from database 40. The section of the distal end corresponding to image 112 is not visible to capturing device 68.


The processor registers the two overlaid images, image 110 and image 112, with each other, and the registration is possible since by tracking device 38 the processor is aware of the location of the device distal end with respect to the captured image. Thus, there is no misalignment between stored image 112, corresponding to the lower portion of the distal end, and image 114 of the upper portion of the distal end, which is included in captured image 110.


However, there is typically misalignment between the two registered overlaid images 110, 112 and the directly visible portion of scene 101, including the directly visible portion of incision 104, as is illustrated in the figure. The misalignment occurs because while the captured image of the ROI is close to that seen by the professional (in the absence of the occlusion mask), it is not exactly in registration with the viewed scene. The inventors have found that a misalignment of up to 2 cm, in a scene that is 50 cm from the eye of the professional, is acceptable.



FIGS. 3A and 3B are schematic diagrams illustrating assembly 24 in different orientations with respect to ROI 34, FIG. 3C is a schematic diagram illustrating angles of the assembly for the different orientations, and FIGS. 3D, 3E are graphs of the angles, according to an embodiment of the present invention. For simplicity, combiner frames 82 are not shown in the diagrams. In FIGS. 3A and 3B processor 26 has positioned masks so that they act to occlude ROI 34 from eyes 120A, 120B of professional 22, specifically from pupils 124A, 124B of the professional's eyes. FIG. 3A illustrates a situation where ROI 34 is approximately directly in front of professional 22. In this case the processor forms mask 80A′ to be on a straight line with pupil 124A and ROI 34, while simultaneously forming mask 80W to be on a straight line with pupil 124B and the region of interest.



FIG. 3B illustrates a situation where ROI 34 is not directly in front of professional 22, but is towards one side of the professional. As for the situation of FIG. 3A the processor forms mask 80A″ to be on a straight line with pupil 124A and ROI 34, and forms mask 80W to be on a straight line with pupil 124B and the region of interest. In all cases masks 80 act as occlusion masks, and, as is illustrated by the differences in the positions of the masks, the processor changes the locations of the masks to account for changes in orientation of the region of interest with respect to assembly 24.


A ring 130 surrounding ROI 34 is described in more detail below.



FIG. 3C schematically illustrates the two situations of FIGS. 3A and 3B, when ROI 34 is at a distance L from eyes 120A, 120B of the professional. Eyes 120A and 120B are separated by a distance w. For the situation of FIG. 3A, where the region of interest is directly in front of the professional, ROI 34 is at a location 103. For the situation of FIG. 3B, ROI 34 is to the left of the professional, at a location 104 that is a distance R from location 103.


For the first situation, where professional 22 is looking at location 103, the directions of gaze, αR, αL of the professional are shown by lines 103R and 103L. αR, αL are angles that are measured with respect to lines orthogonal to a line connecting eyes 120A, 120B, and their values are given by the following equations:











α
L

=

-

arctan

(

w

2

L


)



,


α
R

=

+

arctan

(

w

2

L


)







(
A
)







For the first situation processor 26 rotates combiners 52A and 52B (for clarity the combiners are not shown in the figure for the first situation), within their respective frames 80A and 80B, so that they are orthogonal to lines 103L and 103R. Thus the orientation of the combiners to their frames is given by equations (A).


For the second situation, where professional 22 is looking at location 105, the directions of gaze of the professional are shown by lines 105L and 105R. These directions are respectively changed from the “straight ahead” directions by βL, βR The values of βL, βR are given by equations (B):










β
L

=

acos
(






(

w
2

)

2

+

L
2



-

R


1
+


4


L
2



w
2










(

R
-

w
2


)

2

+

L
2




)





(
B
)










β
R

=

acos
(






(

w
2

)

2

+

L
2



+

R


1
+


4


L
2



w
2










(

R
+

w
2


)

2

+

L
2




)





For the second situation processor 26 rotates combiners 52A and 52B, within their respective frames 80A and 80B, so that they are orthogonal to lines 105L and 105R. Thus the orientation of the combiners to their frames is given by equations (B), and these orientations are illustrated in the figure.



FIG. 3D is a graph of angles βL, βR vs. R for values of L=512 mm, w=60 mm FIG. 3E is a graph of absolute angles γL, γR, of the angles made by combiners 52A, 52B with their frames where

γL,=βLLR,=βRR  (C)


From the above equations, as well as from the graphs, it is apparent that the angles made by combiners 52A, 52B with their respective frames are different, as professional 26 gazes at a region of interest. In addition, if the professional changes his/her gaze, the changes of the combiner angles to maintain orthogonality with the gaze directions are also different.


It will be understood that calculations based on equations herein, including equations (A), (B), and (C), assume that combiners 52A, 52B transmit rays that are orthogonal to the combiners. Those having ordinary skill in the art will be able to adapt the calculations, mutatis mutandis, for situations where the combiners transmit non-orthogonal rays.



FIG. 4 is a schematic diagram illustrating derivation of the dimensions of occlusion mask 80, according to an embodiment of the present invention. FIG. 4 is derived from a section of FIG. 3B, specifically the section illustrating eye 120A, with its pupil 124A, being occluded by mask 80A″ while the eye is gazing at ROI 34. FIG. 4 illustrates a cross-section of the eye, the occlusion mask, and the region of interest. The figure has been drawn on xy axes with an origin O of the axes at the center of pupil 124 and the directions of the x and y axes being respectively orthogonal to and in the plane of the pupil. Mask 80A″ and ROI 34 are assumed to be orthogonal to, and to be symmetrically disposed with respect to, the x-axis. Pupil 124 is assumed to be substantially circular. For simplicity, mask 80A″ and ROI 34 are also assumed to be substantially circular. However, those having ordinary skill in the art will be able to adapt the following description, mutatis mutandis, for regions of interest and occlusion masks that are non-circular, so that the scope of the present invention is assumed to comprise both circular and non-circular regions of interests and masks.


The diagram has been drawn assuming that mask 80A″ just completely occludes ROI 34. Thus a ray HB, from an upper edge H of ROI 34 to an upper edge B of pupil 124A touches an upper edge F of mask 80A″. Similarly, a ray GA, from a lower edge G of ROI 34 to a lower edge A of pupil 124A touches a lower edge E of mask 80A″. Rays HB and GA are assumed to cross at an imaginary point J. A line from upper pupil edge B parallel to the x-axis cuts mask 80A″ at K and ROI 34 at M.


In the description below:

    • p is the apparent diameter of pupil 124A, as measured externally to eye 120A, corresponding to AB; and
    • d is the diameter of mask 80A″, corresponding to EF; d=d1 for a realistic case of p>0, d=d0 is the diameter of the mask for a theoretical “pinhole” case of p=0.
    • In addition,
    • D is the diameter of ROI 34 (which is occluded by mask 80A″), corresponding to GH;
    • L is the distance from pupil 124A to ROI 34;
    • 11 is the distance from pupil 124A to point J; and
    • 1 is the distance from pupil 124A to mask 80A″.


In FIG. 4 ΔJFE, III ΔJHG, so that










d
D

=


l
+

l
1



L
+

l
1







(
1
)







From equation (1),









d
=



l
+

l
1



L
+

l
1



·
D





(
2
)







If 11=0, (for the theoretical case of p=0), then









d
=


d
0

=


l
L

·
D






(
3
)







If 11>0, for the realistic case of p>0, then









d
=


d
1

=



l
+

l
1



L
+

l
1



·
D






(
4
)







ΔBFK III ΔBHM, so that








F

K


B

K


=


F

M


B

M







(5)


For p>0 (so d=d1) and substituting values of d1, p, 1, and L for FK, BK, FM, and BM in equation (5) gives:













d
1

2

-

p
2


l

=



D
2

-

p
2


L





(
6
)







Equation (6) rearranges to:










d
1

=



l

(

D
-
p

)

L

+
p





(
7
)







Equation (7) gives dimensions of mask 80A″, i.e., its diameter d1, in terms of the diameter D of ROI 34, the distance 1 of the mask from the pupil, the diameter of the pupil, and the distance L of the ROI from the pupil.


For typical values of 1=2 cm, L=50 cm, p=0.3 cm, and D=15 cm the diameter of mask 80A″ to just give complete occlusion is, from equation (7), approximately 0.9 cm. For the same values but with p=0.15, the mask diameter is approximately 0.7 cm.


While, as described above, mask 80A″ completely occludes ROI 34, there are regions outside ROI 34 that are partly occluded by the mask. The partial occlusion follows from the finite, non-zero diameter of the pupil of eye, in the example described here pupil 124A, and is described in more detail with reference to FIG. 5 below.



FIG. 5 is a schematic diagram illustrating partial occlusion of an area around ROI 34, by mask 80A″, according to an embodiment of the present invention. FIG. 5 is based upon FIG. 4, but for clarity some of the elements of FIG. 4 are omitted in FIG. 5, while other elements are added in. Thus, a line through point A, parallel to the x-axis, cuts ROI 34 at N. A point Q, lying in the same plane as ROI 34, and at a distance R from the x-axis, is assumed to project two rays—a lower ray 150 which touches lower edge A of the pupil, and an upper ray which, but for the presence of mask 80A″, would touch upper edge B of the pupil. Point Q is thus partly occluded by mask 80A″.


In FIG. 5 at a distance x1 from the pupil lower ray 150 is assumed to be a distance f1(x1) from the x-axis, and upper ray 160 is assumed to be a distance f2(x1) from the x-axis. A line parallel to the y-axis, at x1, cuts BM at S, AN at T, upper ray 160 at V and lower ray 150 at W. Upper ray 160 cuts mask 80A″ at V′, and lower ray 150 cuts a plane containing the mask at W′.


At mask 80A″ the distances of lower ray 150 and of upper ray 160 from the x-axis are respectively f1(1) and f2(1), and the width of the beam between the upper and lower rays is:

f1(1)−f2(1)  (8)


From the diagram,


partial occlusion occurs if:










f

1


(
l
)


>


d
2



and


f

2


(
l
)


<

d
2





(
9
)







no occlusion occurs if:










f

2


(
l
)




d
2





(
10
)









    • and full occlusion, corresponding to the situation illustrated by FIG. 4, occurs if:













f

1


(
l
)




d
2





(
11
)







From expressions (8) and (9), and inspection of FIG. 5, an equation for the fraction F2D of occlusion occurring is:










F

2

D


=



d
2

-

f

2


(
l
)





f

1


(
l
)


-

f

2


(
l
)








(
12
)







(The subscript 2D indicates that the fraction considered here is for the two-dimensional case illustrated in FIGS. 4 and 5. A fraction for the three-dimensional case is referred to below.)


Since ΔATW III ΔANQ










f

1


(
l
)


=



l
L



(

R
-

p
2


)


+

p
2






(
13
)







Since ΔBSV III ΔBMQ










f

2


(
l
)


=



l
L



(

R
+

p
2


)


-

p
2






(
14
)







From equations (13 and (14) the diameter of the cone cross-section from Q at mask 80A″, which is f1(1)−f2(1), is given by:











f

1


(
l
)


-

f

2


(
l
)



=



V




W



=

p

(

1
-

l
L


)






(
15
)







Substituting equations (14) and (15) into equation (12) gives the following expression for F2D:










F

2

D


=



V



E


V



W




=



d
2

-


l
L



(

R
+

p
2


)


+

p
2



p
(

1
-

l
L


)







(
16
)







Inspection of equation (16) indicates that the fraction of occlusion at point Q is a function of pupil diameter p, and also decreases linearly as R increases.


HG is a cross-section of circular ROI 34, so that it will be understood that GQ is a cross-section of a circular, partially occluded circular ring 130 surrounding ROI 34. As illustrated in FIG. 5, there is a point Q′, having the same distance R as Q from the x-axis (but on the opposite side of the axis), and in the same plane as ROI 34, so that HQ′ is also a cross-section of ring 130.


The rays from point Q define a cone of rays emanating from Q, and this cone cuts mask 80A″ in a circle having a diameter VW, the diameter being given by equation (15). The cutting of mask 80A″ by the cone of rays from Q is described with reference to FIG. 6 below.



FIG. 6 illustrates mask 80A″ drawn in a plane orthogonal to the x-axis, according to an embodiment of the present invention. A circle 170, which has a diameter given by equation (15), is the circle cutting the plane containing mask 80A″. A portion 174 of this circle is occluded by circular mask 80A″, and a portion 178 is transmitted. The expression for the two-dimensional fraction of occlusion F2D given by equation (16) corresponds to analysis along a line FV′EW′.


There is a corresponding equation for a three-dimensional fraction of occlusion F3D, given by the following expression:










F

3

D


=

A

A
L






(
17
)









    • where A is the area of portion 174, and

    • AL is the area of circle 170.

    • F3D may also be written as:













F

3

D


=


A

A
L


=





α
1




D
L
2

4


+


α
2




d
2

4


-

M



D
L

2



sin

(

α
1

)




π



D
L
2

4



=


1

π




p
2

(

1
-

l
L


)

2





(



acos

(





p
2

(

1
-

l
L


)

2

+

4



(

R


l
L


)

2


-

d
2



4

R


l
L



p

(

1
-

l
L


)



)





p
2

(

1
-

l
L


)

2


+


acos

(



d
2

+

4



(

R


l
L


)

2


-



p
2

(

1
-

l
L


)

2



4

R


l
L


d


)



d
2


-

2

R


l
L



p

(

1
-

l
L


)



sin

(

acos

(





p
2

(

1
-

l
L


)

2

+

4



(

R


l
L


)

2


-

d
2



4

R


l
L



p

(

1
-

l
L


)



)

)



)








(
18
)







From equation (18), F3D is a function of pupil diameter p, and the equation provides numerical values of F3D for selected values of d, R, p, 1, and L.



FIG. 7 illustrates graphs of occlusion vs. distance, according to an embodiment of the present invention. The graphs have been drawn assuming the following values:

    • L=50 cm
    • 1=2 cm
    • P=0.3 cm
    • D=15 cm


From equation (7) the diameter of the occlusion mask to fully occlude an ROI with diameter D of 15 cm is d=0.888 cm. The graphs of FIG. 7 have been drawn with d set at 0.894 cm.


From equation (15) the diameter of circle 170 is 0.288 cm, so that the value of the area AL of the circle is 0.065144 cm2.


A solid line graph 200 illustrates the full and partial occlusion vs. distance (from the center of the ROI) for the three-dimensional case comprising equation (18). The measurements of occlusion have been normalized, so that for an LCD screen a full occlusion of 95% is normalized to 1, and a full transparency (of 60% occlusion) is normalized to 0. A broken line graph 204 illustrates the full and partial occlusion vs. distance for the two-dimensional case comprising equation (16). As is apparent from both graphs, there is full occlusion, for a mask of diameter d=0.894 cm, for a region 208 up to approximately 8 cm from the center of the ROI, and partial occlusion in a region 212 from approximately 8 cm to approximately 15 cm. The fraction of partial occlusion decreases monotonically in region 212.



FIG. 8 is a flowchart of steps performed in operation of system 20, according to an embodiment of the present invention. The steps are assumed to be performed by processor 26 and, as necessary, professional 22 for use in a procedure on patient 30 performed by the professional using device 38 (FIG. 1). In an initial calibration step 300, frame 54 is adjusted to center combiners 52 with respect to the eyes of the professional. The sizes of the combiners and the distances of the combiners from the eyes of the professional are also measured and recorded by the processor (the use of the measurements is described further below). In step 300 assembly 24 is calibrated, i.e. optical elements of the assembly are registered with each other. Thus, devices 68 are oriented on frame 54 to capture generally similar images from the region in front of combiners 52. If sensor 72 is present it is also aligned to capture a corresponding non-visible image from the region.


Processor 26 also orients the images from micro-projectors 64, by registering the images projected by the micro-projectors onto combiners 52 with the scene viewed by professional 22 through the combiners. The registration may be accomplished by the professional viewing a scene through combiners 52, together with an image of the same scene as it is captured by devices 60 and projected by the micro-projectors onto the combiners. The professional then adjusts the orientation of the micro-projectors and/or the capturing devices so that the projected image and the viewed scene coincide.


Typically the registration and adjustment of the micro-projectors and the capturing devices is performed for different regions of combiners 52, such as the left and right peripheral regions, the upper and lower peripheral regions, and a central region. In addition, the registration and adjustment may be performed for different scenes according to the distance of the scene from the combiner, such as a scene of relatively near elements, typically up to 1 m from the combiner, and a scene of relatively far elements, typically greater than 1 m from the combiner. The registrations and adjustments of the micro-projectors and the capturing devices are typically different for the different regions of the combiners, as well as for scenes at different distances from the combiners. Processor 26 stores the different registration data acquired during the calibration step for use when the professional is using assembly 24.


During the calibration step the sizes of the pupils of the eyes of professional 22 are measured. In one embodiment professional 22 gazes at a circular object of a known diameter and at a known distance from the professional, and processor 26 presents an occlusion mask on screens 60 to the professional. The professional then adjusts a diameter of the occlusion mask until complete occlusion of the object is achieved. As is apparent from equation (7), the diameter of the completely occluding mask provides a value for the pupil diameter, since d1, 1, L and D (terms in equation (7)) are all known.


Alternatively or additionally, the professional may look into a mirror while image capturing devices 60 acquire images of the reflected scene, in this case the professional wearing assembly 24. Processor 26 analyzes the acquired images, by processes that are well known in the art, to identify the pupils of the professional as well as the outlines of combiners 52. The processor then compares the diameters of the pupils with the known dimensions of the combiners, so as to determine values for the diameters.


The measurements of the pupil diameters are taken for different ambient light brightnesses, and the ambient brightness values may be determined from the signal levels of the images acquired by devices 68. Processor 26 stores the values of the pupil diameters, and the corresponding brightness levels.


As stated above, processor 26 is configured to track device 38, using the one or more identifying elements 39 (FIG. 1). In calibration step 300 the processor initiates tracking of device 38, and professional 22 confirms that the tracking is acceptable.


In an ROI defining step 302, ROI acquisition marker 35 (FIG. 1) is positioned on patient 30, so as to define a region of interest of the patient selected by the professional, herein assumed to be ROI 34. As explained above, marker elements 36 of marker 35 define the position of ROI 34, and the size of the ROI may be defined by the professional. Typically there are at least three marker elements 36, although more may be used, and characteristics of the elements, such as their color and/or shape, are selected so that they may be easily distinguished from patient 30. If assembly 24 comprises sensor 72 with an infra-red projector, marker elements 36 may be configured as retro-reflectors which selectively reflect only infra-red radiation.


In an imaging step 304, image capturing devices 68 acquire images of the scene in front of assembly 24. Sensor 72, if present, also captures a corresponding image of the scene. Processor 26 analyzes the images to identify marker elements 36, and from the identified elements determines the orientation of ROI 34 with respect to assembly 24, and also the distance of the ROI from the assembly. Even if sensor 72 is not present, it will be understood that having two devices 68 acquiring respective images of the scene simplifies the analysis needed to be performed by the processor to identify elements 36. In addition, having two capturing devices 68 reduces the number of elements 36 required to accurately determine the orientation and distance of the ROI with respect to assembly 24, compared to the number required if only one capturing device 68 is used. With two capturing devices 68 the inventors have found it is sufficient to have one marker with three marker elements to accurately locate the ROI with respect to assembly 24. If sensor 72 is present, its image alone may be sufficient to identify elements 36, although typically processor 26 uses the images from devices 68 to improve the accuracy of the orientation and distance measures of the ROI determined by the sensor.


Processor 26 also analyzes the images acquired by devices 68 in order to determine a measure of the brightness of the scene in front of assembly 24.


In a frame orientation step 305, the processor rotates combiners 52A and 52B with respect to their respective frames so that the combiners are orthogonal to the gaze directions of the professional towards the ROI. The processor uses equations (A), (B) and/or (C) to determine the angles of rotation of the combiners.


In a masking step 306, the processor generates circular occlusion masks 80 in screens 60. The processor, using the orientation of the ROI measured in step 304 and the central adjustment of combiners 52 in step 300, determines positions for the masks that will occlude ROI 34. From the brightness measured in step 304, and from the correspondence between pupil size and brightness stored in initial step 300, the processor estimates a value of the pupil diameter of the professional.


In one embodiment the processor sets the diameter of masks 80 according to equation (7), i.e., inter alia, according to the professional's pupil size, so that the masks fully occlude ROI 34. In this case partially occluded ring 130 surrounds ROI 34, the fraction of partial occlusion within the ring being given by equations (12) and (18).


In some embodiments the processor determines sections of the scene corresponding to partially occluded ring 130, and as acquired by devices 68. The processor then configures micro-projectors 64 to overlay video of the acquired sections onto the partially occluded ring, so as to compensate for the partial occlusion. Typically, processor configures the intensity of the projected video to be the inverse of the fraction of the occlusion.


In an alternative embodiment, rather than setting the diameter of the masks to be according to equation (7), the processor sets the diameter to be reduced from the value determined by the equation. The reduction is typically determined by professional 22. In one embodiment the diameter is set to be 90% of the value determined by equation (7).


In a further alternative embodiment, the processor, using instructions from professional 22, sets the diameter of the masks to be larger than the diameter of equation (7). In one embodiment the diameter is set to be 110% of the value determined by equation (7).


In a mask projection step 308 processor 26 uses micro-projectors 64 to project augmented video onto occlusion masks 80. In the case of the augmented video including two or more types of images being projected onto the masks, processor 26 registers the images with each other. However, the images are not necessarily registered, and are typically misaligned, with the scene surrounding and outside the masks. Thus, as exemplified by FIG. 2E and the description of the figure, a video image 114 of the upper portion of the distal end of device 38, together with a stored image 112 corresponding to the lower portion of the distal end, are registered together and are projected onto masks 80. As is also illustrated in FIG. 2E, the images on masks 80 are typically misaligned with the visible scene outside the masks.


In a further projection step 310, processor 26 uses micro-projectors 64 to project augmented video onto the partially occluded ring surrounding the masks, and/or the non-occluded section of combiners 52. As in step 308, multiple image types are registered together, but are typically misaligned with the visible scene of the non-occluded section.


Typical images that are projected in steps 308 and 310 include, but are not limited to, those described above with respect to FIGS. 2C, 2D, and 2E, and the choice and positioning of the images is typically under the overall control of professional 22. In a mentoring situation, at least some of the images are typically under control of a mentor of professional 22.


It will be appreciated that the embodiments described above are cited by way of example, and that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof which would occur to persons skilled in the art upon reading the foregoing description and which are not disclosed in the prior art.

Claims
  • 1. A head-mounted augmented reality near eye display device configured to facilitate a medical procedure, the device comprising: a retaining structure that is configured to be positioned in proximity to eyes of a wearer of the device;at least one processor mounted on or in the retaining structure, the at least one processor configured to access a database;two optical combiners mounted on the retaining structure and positioned so as to be in front of a respective one of the eyes of the wearer,wherein each of the optical combiners is configured to at least partially transmit elements of a scene through the optical combiner so that a portion of a region of interest of a patient is directly visible through the optical combiner,wherein the optical combiners are configured to be rotated about a horizontal axis so that they can tilt downwards at an angle of up to 40 degrees from horizontal;two lenses, each of the two lenses positioned between a respective one of the two optical combiners and a respective one of the eyes of the wearer,two micro-projectors mounted on the retaining structure, each micro-projector located and oriented so as to be able to project a selected image from the database onto a respective one of the two optical combiners,wherein each of the two lenses redirects light from a respective optical combiner so that the projected image appears to be closer than infinity to the eyes of the wearer of the device,wherein the selected image is adapted to be in focus at approximately 50 cm; andan infrared sensor mounted on or in the retaining structure, the infrared sensor configured to capture images of at least one marker positioned near a region of interest associated with the medical procedure.
  • 2. The device of claim 1, wherein the retaining structure comprises a spectacle frame.
  • 3. The device of claim 1, wherein the retaining structure comprises a helmet.
  • 4. The device of claim 1, wherein each of the two optical combiners comprises a variable transparency screen that is configured to at least partially transmit elements of a scene through the respective optical combiner so that a portion of the region of interest is directly visible through the respective optical combiner.
  • 5. The device of claim 4, wherein the screen is pixelated.
  • 6. The device of claim 5, wherein the screen is formed of an array of liquid crystal pixels.
  • 7. The device of claim 6, wherein the array is a rectangular array.
  • 8. The device of claim 4, wherein the at least one processor is configured to render at least a section of the screen at least partially opaque.
  • 9. The device of claim 8, wherein the section is a circular section.
  • 10. The device of claim 1, wherein the optical combiners are of a waveguide type.
  • 11. The device of claim 1, wherein the optical combiners comprise see through glasses.
  • 12. The device of claim 1, wherein the optical combiners are configured to be independently rotated.
  • 13. A head-mounted augmented reality near eye display device configured to facilitate a medical procedure, the device comprising: a retaining structure that is configured to be positioned in proximity to eyes of a wearer of the device;at least one processor mounted on or in the retaining structure, the at least one processor configured to access a database;two optical combiners mounted on the retaining structure and positioned so as to be in front of a respective one of the eyes of the wearer,wherein each of the optical combiners is configured to at least partially transmit elements of a scene through the optical combiner so that a portion of a region of interest of a patient is directly visible through the optical combiner,two lenses, each of the two lenses positioned between a respective one of the two optical combiners and a respective one of the eyes of the wearer,two micro-projectors mounted on the retaining structure, each micro-projector located and oriented so as to be able to project a selected image from the database onto a respective one of the two optical combiners,wherein each of the two lenses redirects light from a respective optical combiner so that the projected image appears to be closer than infinity to the eyes of the wearer of the device, andwherein the selected image is adapted to be in focus at approximately 50 cm.
  • 14. The device of claim 13, wherein the retaining structure comprises a spectacle frame.
  • 15. The device of claim 13, wherein the retaining structure comprises a helmet.
  • 16. The device of claim 13, wherein each of the two optical combiners comprises a variable transparency screen that is configured to at least partially transmit elements of a scene through the respective optical combiner so that a portion of the region of interest is directly visible through the respective optical combiner.
  • 17. The device of claim 16, wherein the screen is pixelated.
  • 18. The device of claim 17, wherein the screen is formed of an array of liquid crystal pixels.
  • 19. The device of claim 13, further comprising an infrared sensor mounted on or in the retaining structure, the infrared sensor configured to capture images of at least one marker positioned near a region of interest associated with the medical procedure.
  • 20. The device of claim 13, wherein each of the optical combiners comprises a waveguide configured to transmit light coming from a respective micro-projector into the respective one of the eyes of the wearer so as to display the selected image from the database as an augmented reality display.
Priority Claims (1)
Number Date Country Kind
1504935 Mar 2015 GB national
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/419,023, filed May 22, 2019, which is a continuation of U.S. patent application Ser. No. 16/159,740, filed Oct. 15, 2018 (now U.S. Pat. No. 10,382,748), which is a continuation of U.S. patent application Ser. No. 15/896,102, filed Feb. 14, 2018 (now U.S. Pat. No. 10,134,166), which is a continuation of U.S. patent application Ser. No. 15/127,423, filed Sep. 20, 2016 (now U.S. Pat. No. 9,928,629), which is a national stage entry of PCT Patent Application PCT/IB2016/051642, filed Mar. 23, 2016, which claims the benefit of U.K. Patent Application GB1504935.6, filed Mar. 24, 2015, each of which is incorporated herein by reference in its entirety.

US Referenced Citations (1274)
Number Name Date Kind
3101715 Glassman Aug 1963 A
3690776 Zaporoshan Sep 1972 A
4459358 Berke Jul 1984 A
4711512 Upatnieks Dec 1987 A
4863238 Brewster Sep 1989 A
4944739 Torre Jul 1990 A
5147365 Whitlock et al. Sep 1992 A
5357292 Wiedner Oct 1994 A
5441042 Putman Aug 1995 A
5442146 Bell et al. Aug 1995 A
5510832 Garcia Apr 1996 A
D370309 Stucky May 1996 S
5636255 Ellis Jun 1997 A
5665092 Mangiardi et al. Sep 1997 A
5771121 Hentschke Jun 1998 A
5792046 Dobrovolny Aug 1998 A
5841507 Barnes Nov 1998 A
6006126 Cosman Dec 1999 A
6038467 De Bliek et al. Mar 2000 A
6125164 Murphy et al. Sep 2000 A
6147805 Fergason Nov 2000 A
6227667 Halldorsson et al. May 2001 B1
6256529 Holupka et al. Jul 2001 B1
6285505 Melville et al. Sep 2001 B1
6314310 Ben-Haim et al. Nov 2001 B1
6349001 Spitzer Feb 2002 B1
6444192 Mattrey Sep 2002 B1
6447503 Wynne et al. Sep 2002 B1
6449090 Omar et al. Sep 2002 B1
6456405 Horikoshi et al. Sep 2002 B2
6456868 Saito et al. Sep 2002 B2
6474159 Foxlin et al. Nov 2002 B1
6518939 Kikuchi Feb 2003 B1
6527777 Justin Mar 2003 B2
6529331 Massof et al. Mar 2003 B2
6549645 Oikawa et al. Apr 2003 B1
6578962 Amir et al. Jun 2003 B1
6609022 Mlsmeier et al. Aug 2003 B2
6610009 Person Aug 2003 B2
D480476 Martinson et al. Oct 2003 S
6659611 Amir et al. Dec 2003 B2
6675040 Cosman Jan 2004 B1
6683584 Ronzani et al. Jan 2004 B2
6690964 Bieger et al. Feb 2004 B2
6714810 Grzeszczuk et al. Mar 2004 B2
6737425 Yamamoto et al. May 2004 B1
6740882 Weinberg May 2004 B2
6757068 Foxlin Jun 2004 B2
6759200 Stanton, Jr. Jul 2004 B1
6847336 Lemelson et al. Jan 2005 B1
6856324 Sauer et al. Feb 2005 B2
6856826 Seeley et al. Feb 2005 B2
6891518 Sauer et al. May 2005 B2
6900777 Hebert et al. May 2005 B1
6919867 Sauer Jul 2005 B2
6921167 Nagata Jul 2005 B2
6966668 Cugini et al. Nov 2005 B2
6980849 Sasso Dec 2005 B2
6993374 Sasso Jan 2006 B2
6997552 Hung Feb 2006 B1
6999239 Martins et al. Feb 2006 B1
7000262 Bielefeld Feb 2006 B2
7035371 Boese et al. Apr 2006 B2
7043961 Pandey et al. May 2006 B2
7072435 Metz et al. Jul 2006 B2
7103233 Stearns Sep 2006 B2
7107091 Jutras et al. Sep 2006 B2
7112656 Desnoyers et al. Sep 2006 B2
7141812 Appleby et al. Nov 2006 B2
7157459 Ohta et al. Jan 2007 B2
7169785 Timmer et al. Jan 2007 B2
7171255 Holupka et al. Jan 2007 B2
7176936 Sauer et al. Feb 2007 B2
7187792 Fu et al. Mar 2007 B2
7190331 Genc et al. Mar 2007 B2
7194295 Vilsmeier Mar 2007 B2
7215322 Genc et al. May 2007 B2
7229078 Lechot Jun 2007 B2
7231076 Fu et al. Jun 2007 B2
7235076 Pacheco Jun 2007 B2
7239330 Sauer et al. Jul 2007 B2
7241292 Hooven Jul 2007 B2
7259266 Carter et al. Aug 2007 B2
7260426 Schweikard et al. Aug 2007 B2
7269192 Hayashi Sep 2007 B2
7281826 Huang Oct 2007 B2
7315636 Kuduvalli Jan 2008 B2
7320556 Vagn-Erik Jan 2008 B2
7330578 Wang et al. Feb 2008 B2
7359535 Salla et al. Apr 2008 B2
7364314 Nilsen et al. Apr 2008 B2
7366934 Narayan et al. Apr 2008 B1
7379077 Bani-Hashemi et al. May 2008 B2
7431453 Hogan Oct 2008 B2
7435219 Kim Oct 2008 B2
7450743 Sundar et al. Nov 2008 B2
7458977 McGinley et al. Dec 2008 B2
7462852 Appleby et al. Dec 2008 B2
7493153 Ahmed et al. Feb 2009 B2
7505617 Fu et al. Mar 2009 B2
7507968 Wollenweber et al. Mar 2009 B2
7518136 Appleby et al. Apr 2009 B2
7525735 Sottilare et al. Apr 2009 B2
D592691 Chang May 2009 S
D592692 Chang May 2009 S
D592693 Chang May 2009 S
7536216 Geiger et al. May 2009 B2
7542791 Mire et al. Jun 2009 B2
7556428 Sukovic et al. Jul 2009 B2
7557824 Holliman Jul 2009 B2
7563228 Ma et al. Jul 2009 B2
7567834 Clayton et al. Jul 2009 B2
7570791 Frank et al. Aug 2009 B2
7586686 Hall Sep 2009 B1
D602620 Cristoforo Oct 2009 S
7605826 Sauer Oct 2009 B2
7606613 Simon et al. Oct 2009 B2
7607775 Hermanson et al. Oct 2009 B2
7620223 Xu et al. Nov 2009 B2
7623902 Pacheco Nov 2009 B2
7627085 Boyden et al. Dec 2009 B2
7630753 Simon et al. Dec 2009 B2
7633501 Wood et al. Dec 2009 B2
7645050 Wilt et al. Jan 2010 B2
7653226 Guhring et al. Jan 2010 B2
7657075 Viswanathan Feb 2010 B2
7689019 Boese et al. Mar 2010 B2
7689042 Brunner et al. Mar 2010 B2
7689320 Prisco et al. Mar 2010 B2
7699486 Beiner Apr 2010 B1
7699793 Goette et al. Apr 2010 B2
7719769 Sugihara et al. May 2010 B2
D617825 Chang Jun 2010 S
7734327 Colquhoun Jun 2010 B2
D619285 Cristoforo Jul 2010 S
7751865 Jascob et al. Jul 2010 B2
7758204 Klipstein et al. Jul 2010 B2
7768702 Hirose et al. Aug 2010 B2
7769236 Fiala Aug 2010 B2
7773074 Arenson et al. Aug 2010 B2
7774044 Sauer et al. Aug 2010 B2
7822483 Stone et al. Oct 2010 B2
D628307 Krause-Bonte Nov 2010 S
7826902 Stone et al. Nov 2010 B2
7831073 Fu et al. Nov 2010 B2
7831096 Williamson, Jr. Nov 2010 B2
7835778 Foley et al. Nov 2010 B2
7835784 Mire et al. Nov 2010 B2
7837987 Shi et al. Nov 2010 B2
7840093 Fu et al. Nov 2010 B2
7840253 Tremblay et al. Nov 2010 B2
7840256 Lakin et al. Nov 2010 B2
7853305 Simon et al. Dec 2010 B2
7854705 Pawluczyk et al. Dec 2010 B2
7857271 Lees Dec 2010 B2
7860282 Boese et al. Dec 2010 B2
D630766 Harbin Jan 2011 S
7865269 Prisco et al. Jan 2011 B2
7874686 Rossner et al. Jan 2011 B2
7881770 Melkent et al. Feb 2011 B2
7893413 Appleby et al. Feb 2011 B1
7894649 Fu et al. Feb 2011 B2
7920162 Masini et al. Apr 2011 B2
7922391 Essenreiter et al. Apr 2011 B2
7938553 Beiner May 2011 B1
7945310 Gattani et al. May 2011 B2
7953471 Clayton et al. May 2011 B2
7969383 Eberl et al. Jun 2011 B2
7974677 Mire et al. Jul 2011 B2
7985756 Barlow et al. Jul 2011 B2
7991557 Liew et al. Aug 2011 B2
7993353 Roner et al. Aug 2011 B2
7996064 Simon et al. Aug 2011 B2
8004524 Deinzer Aug 2011 B2
8021300 Ma et al. Sep 2011 B2
8022984 Cheong et al. Sep 2011 B2
8045266 Nakamura Oct 2011 B2
8060181 Rodriguez et al. Nov 2011 B2
8068581 Boese et al. Nov 2011 B2
8068896 Daghighian et al. Nov 2011 B2
8077943 Williams et al. Dec 2011 B2
8079957 Ma et al. Dec 2011 B2
8081812 Kreiser Dec 2011 B2
8085075 Huffman et al. Dec 2011 B2
8085897 Morton Dec 2011 B2
8090175 Fu et al. Jan 2012 B2
8092400 Warkentine et al. Jan 2012 B2
8108072 Zhao et al. Jan 2012 B2
8112292 Simon Feb 2012 B2
8116847 Gattani et al. Feb 2012 B2
8120847 Chang Feb 2012 B2
8121255 Sugiyama Feb 2012 B2
8155479 Hoffman et al. Apr 2012 B2
8180132 Gorges et al. May 2012 B2
8180429 Sasso May 2012 B2
8208599 Ye et al. Jun 2012 B2
8216211 Mathis et al. Jul 2012 B2
8221402 Francischelli et al. Jul 2012 B2
8239001 Verard et al. Aug 2012 B2
8244012 Liang et al. Aug 2012 B2
8253778 Atsushi Aug 2012 B2
8271069 Jascob et al. Sep 2012 B2
8280491 Kuduvalli et al. Oct 2012 B2
8285021 Boese et al. Oct 2012 B2
8300315 Kobayashi Oct 2012 B2
8305685 Heine et al. Nov 2012 B2
8306305 Porat et al. Nov 2012 B2
8309932 Haselman et al. Nov 2012 B2
8317320 Huang Nov 2012 B2
8328815 Farr et al. Dec 2012 B2
8335553 Rubner et al. Dec 2012 B2
8335557 Maschke Dec 2012 B2
8340379 Razzaque et al. Dec 2012 B2
8369925 Giesel et al. Feb 2013 B2
8386022 Jutras et al. Feb 2013 B2
8394144 Zehavi et al. Mar 2013 B2
8398541 Dimaio et al. Mar 2013 B2
8444266 Waters May 2013 B2
8457719 Moctezuma De La Barrera et al. Jun 2013 B2
8467851 Mire et al. Jun 2013 B2
8469902 Dick et al. Jun 2013 B2
8475470 Von Jako Jul 2013 B2
8494612 Vetter et al. Jul 2013 B2
8509503 Nahum et al. Aug 2013 B2
8511827 Hua et al. Aug 2013 B2
8531394 Maltz Sep 2013 B2
8540364 Waters Sep 2013 B2
8545012 Waters Oct 2013 B2
8548567 Maschke et al. Oct 2013 B2
8556883 Saleh Oct 2013 B2
8559596 Thomson et al. Oct 2013 B2
8567945 Waters Oct 2013 B2
8571353 Watanabe Oct 2013 B2
8585598 Razzaque et al. Nov 2013 B2
8600001 Schweizer Dec 2013 B2
8600477 Beyar et al. Dec 2013 B2
8605199 Imai Dec 2013 B2
8611988 Miyamoto Dec 2013 B2
8612024 Stone et al. Dec 2013 B2
8634897 Simon et al. Jan 2014 B2
8641621 Razzaque et al. Feb 2014 B2
8643950 König Feb 2014 B2
8644907 Hartmann et al. Feb 2014 B2
8674902 Park et al. Mar 2014 B2
8686923 Eberl et al. Apr 2014 B2
8690581 Ruf et al. Apr 2014 B2
8690776 Razzaque et al. Apr 2014 B2
8692845 Fedorovskaya et al. Apr 2014 B2
8693632 Allison Apr 2014 B2
8694075 Groszmann et al. Apr 2014 B2
8699765 Hao et al. Apr 2014 B2
8705829 Frank et al. Apr 2014 B2
8737708 Hartmann et al. May 2014 B2
8746887 Shestak et al. Jun 2014 B2
8784450 Moskowitz et al. Jul 2014 B2
8786689 Liu Jul 2014 B1
D710545 Wu Aug 2014 S
D710546 Wu Aug 2014 S
8827934 Chopra et al. Sep 2014 B2
8831706 Fu et al. Sep 2014 B2
8836768 Rafii et al. Sep 2014 B1
8838199 Simon et al. Sep 2014 B2
8848977 Bammer et al. Sep 2014 B2
8855395 Baturin et al. Oct 2014 B2
8878900 Yang et al. Nov 2014 B2
8879815 Miao et al. Nov 2014 B2
8885177 Ben-Yishai et al. Nov 2014 B2
8890772 Woo et al. Nov 2014 B2
8890773 Pederson Nov 2014 B1
8890943 Lee et al. Nov 2014 B2
8897514 Feikas et al. Nov 2014 B2
8900131 Chopra et al. Dec 2014 B2
8903150 Star-Lack et al. Dec 2014 B2
8908952 Isaacs et al. Dec 2014 B2
8911358 Koninckx et al. Dec 2014 B2
8917268 Johnsen et al. Dec 2014 B2
8920776 Gaiger et al. Dec 2014 B2
8922589 Laor Dec 2014 B2
8941559 Bar-Zeev et al. Jan 2015 B2
8942455 Chou et al. Jan 2015 B2
8950877 Northey et al. Feb 2015 B2
8953246 Koenig Feb 2015 B2
8965583 Ortmaier et al. Feb 2015 B2
8969829 Wollenweber et al. Mar 2015 B2
8989349 Thomson et al. Mar 2015 B2
8992580 Bar et al. Mar 2015 B2
8994729 Nakamura Mar 2015 B2
8994795 Oh Mar 2015 B2
9004711 Gerolemou Apr 2015 B2
9005211 Brundobler et al. Apr 2015 B2
9011441 Bertagnoli et al. Apr 2015 B2
9057759 Klingenbeck et al. Jun 2015 B2
9060757 Lawson et al. Jun 2015 B2
9066751 Sasso Jun 2015 B2
9081436 Berme et al. Jul 2015 B1
9084635 Nuckley et al. Jul 2015 B2
9085643 Svanborg et al. Jul 2015 B2
9087471 Miao Jul 2015 B2
9100643 McDowall et al. Aug 2015 B2
9101394 Arata et al. Aug 2015 B2
9104902 Xu et al. Aug 2015 B2
9111175 Strommer et al. Aug 2015 B2
9123155 Cunningham et al. Sep 2015 B2
9125556 Zehavi et al. Sep 2015 B2
9129054 Nawana et al. Sep 2015 B2
9129372 Kriston et al. Sep 2015 B2
9132361 Smithwick Sep 2015 B2
9135706 Zagorchev et al. Sep 2015 B2
9141873 Takemoto Sep 2015 B2
9142020 Deguise et al. Sep 2015 B2
9149317 Arthur et al. Oct 2015 B2
9165203 McCarthy Oct 2015 B2
9165362 Siewerdsen et al. Oct 2015 B2
9179984 Teichman et al. Nov 2015 B2
D746354 Chang Dec 2015 S
9208916 Appleby et al. Dec 2015 B2
9220573 Kendrick et al. Dec 2015 B2
9225895 Kozinski Dec 2015 B2
9232982 Soler et al. Jan 2016 B2
9235934 Mandella et al. Jan 2016 B2
9240046 Carrell et al. Jan 2016 B2
9244278 Sugiyama et al. Jan 2016 B2
9247240 Park et al. Jan 2016 B2
9259192 Ishihara Feb 2016 B2
9265572 Fuchs et al. Feb 2016 B2
9269192 Kobayashi Feb 2016 B2
9283052 Rodriguez Ponce Mar 2016 B2
9286730 Bar-Zeev et al. Mar 2016 B2
9289267 Sauer et al. Mar 2016 B2
9294222 Proctor, Jr. Mar 2016 B2
9300949 Ahearn Mar 2016 B2
9310591 Hua et al. Apr 2016 B2
9320474 Demri et al. Apr 2016 B2
9323055 Baillot Apr 2016 B2
9330477 Rappel May 2016 B2
9335547 Takano et al. May 2016 B2
9335567 Nakamura May 2016 B2
9341704 Picard et al. May 2016 B2
9344686 Moharir May 2016 B2
9349066 Koo et al. May 2016 B2
9349520 Demetriou et al. May 2016 B2
9364294 Razzaque et al. Jun 2016 B2
9370332 Paladini et al. Jun 2016 B2
9373166 Azar Jun 2016 B2
9375639 Kobayashi et al. Jun 2016 B2
9378558 Kajiwara et al. Jun 2016 B2
9380287 Nistico et al. Jun 2016 B2
9387008 Sarvestani et al. Jul 2016 B2
9392129 Simmons Jul 2016 B2
9395542 Tilleman et al. Jul 2016 B2
9398936 Razzaque et al. Jul 2016 B2
9400384 Griffith Jul 2016 B2
9414041 Ko et al. Aug 2016 B2
9424611 Kanjirathinkal et al. Aug 2016 B2
9424641 Wiemker et al. Aug 2016 B2
9427286 Siewerdsen et al. Aug 2016 B2
9438894 Park et al. Sep 2016 B2
9443488 Borenstein et al. Sep 2016 B2
9453804 Tahtali Sep 2016 B2
9456878 MacFarlane et al. Oct 2016 B2
9465235 Chang Oct 2016 B2
9468373 Larsen Oct 2016 B2
9470908 Frankel et al. Oct 2016 B1
9473766 Douglas et al. Oct 2016 B2
9492222 Singh Nov 2016 B2
9495585 Bicer et al. Nov 2016 B2
9498132 Maier-Hein et al. Nov 2016 B2
9498231 Haider et al. Nov 2016 B2
9499999 Nanqing Nov 2016 B2
9507155 Morimoto Nov 2016 B2
9513495 Waters Dec 2016 B2
9521966 Schwartz Dec 2016 B2
9526443 Berme et al. Dec 2016 B1
9530382 Simmons Dec 2016 B2
9532846 Nakamura Jan 2017 B2
9532849 Anderson et al. Jan 2017 B2
9538962 Hannaford et al. Jan 2017 B1
9545233 Sirpad et al. Jan 2017 B2
9546779 Rementer Jan 2017 B2
9547174 Gao et al. Jan 2017 B2
9547940 Sun et al. Jan 2017 B1
9557566 Fujimaki Jan 2017 B2
9560318 Reina et al. Jan 2017 B2
9561095 Nguyen et al. Feb 2017 B1
9561446 Brecher Feb 2017 B2
9565415 Zhang et al. Feb 2017 B2
9572661 Robin et al. Feb 2017 B2
9576556 Simmons Feb 2017 B2
9581822 Morimoto Feb 2017 B2
9610056 Lavallee et al. Apr 2017 B2
9612657 Bertram et al. Apr 2017 B2
9629595 Walker et al. Apr 2017 B2
9633431 Merlet Apr 2017 B2
9645395 Bolas et al. May 2017 B2
9646423 Sun et al. May 2017 B1
9672597 Amiot et al. Jun 2017 B2
9672607 Demri et al. Jun 2017 B2
9672640 Kleiner Jun 2017 B2
9675306 Morton Jun 2017 B2
9675319 Razzaque et al. Jun 2017 B1
9684980 Royalty et al. Jun 2017 B2
9690119 Garofolo et al. Jun 2017 B2
RE46463 Fienbloom et al. Jul 2017 E
9693748 Rai et al. Jul 2017 B2
9710968 Dillavou et al. Jul 2017 B2
9713502 Finkman et al. Jul 2017 B2
9724119 Hissong et al. Aug 2017 B2
9724165 Arata et al. Aug 2017 B2
9726888 Giartosio et al. Aug 2017 B2
9728006 Varga Aug 2017 B2
9729831 Birnkrant et al. Aug 2017 B2
9757034 Desjardins et al. Sep 2017 B2
9757087 Simon et al. Sep 2017 B2
9766441 Rappel Sep 2017 B2
9767608 Lee et al. Sep 2017 B2
9770203 Berme et al. Sep 2017 B1
9772102 Ferguson Sep 2017 B1
9772495 Tam et al. Sep 2017 B2
9791138 Feinbloom et al. Oct 2017 B1
9800995 Libin et al. Oct 2017 B2
9805504 Zhang et al. Oct 2017 B2
9808148 Miller et al. Nov 2017 B2
9839448 Reckling et al. Dec 2017 B2
9844413 Daon et al. Dec 2017 B2
9851080 Wilt et al. Dec 2017 B2
9858663 Penney et al. Jan 2018 B2
9861446 Lang Jan 2018 B2
9864214 Fass Jan 2018 B2
9872733 Shoham et al. Jan 2018 B2
9875544 Rai et al. Jan 2018 B2
9877642 Duret Jan 2018 B2
9885465 Nguyen Feb 2018 B2
9886552 Dillavou et al. Feb 2018 B2
9886760 Liu et al. Feb 2018 B2
9892564 Cvetko et al. Feb 2018 B1
9898866 Fuchs et al. Feb 2018 B2
9901414 Lively et al. Feb 2018 B2
9911187 Steinle et al. Mar 2018 B2
9927611 Rudy et al. Mar 2018 B2
9928629 Benishti et al. Mar 2018 B2
9940750 Dillavou et al. Apr 2018 B2
9943374 Merritt et al. Apr 2018 B2
9947110 Haimerl Apr 2018 B2
9952664 Border et al. Apr 2018 B2
9956054 Aguirre-Valencia May 2018 B2
9958674 Border May 2018 B2
9959620 Merlet May 2018 B2
9959629 Dillavou et al. May 2018 B2
9965681 Border et al. May 2018 B2
9968297 Connor May 2018 B2
9980780 Lang May 2018 B2
9986228 Woods May 2018 B2
D824523 Paoli et al. Jul 2018 S
10010379 Gibby et al. Jul 2018 B1
10013531 Richards et al. Jul 2018 B2
10015243 Kazerani et al. Jul 2018 B2
10016243 Esterberg Jul 2018 B2
10022064 Kim et al. Jul 2018 B2
10022065 Ben-Yishai et al. Jul 2018 B2
10022104 Sell et al. Jul 2018 B2
10023615 Bonny Jul 2018 B2
10026015 Cavusoglu et al. Jul 2018 B2
10034713 Yang et al. Jul 2018 B2
10046165 Frewin et al. Aug 2018 B2
10055838 Elenbaas et al. Aug 2018 B2
10066816 Chang Sep 2018 B2
10067359 Ushakov Sep 2018 B1
10073515 Awdeh Sep 2018 B2
10080616 Wilkinson et al. Sep 2018 B2
10082680 Chung Sep 2018 B2
10085709 Lavallee et al. Oct 2018 B2
10105187 Corndorf et al. Oct 2018 B2
10107483 Oren Oct 2018 B2
10108833 Hong et al. Oct 2018 B2
10123840 Dorman Nov 2018 B2
10130378 Bryan Nov 2018 B2
10132483 Feinbloom et al. Nov 2018 B1
10134166 Benishti et al. Nov 2018 B2
10134194 Kepner et al. Nov 2018 B2
10139652 Windham Nov 2018 B2
10139920 Isaacs et al. Nov 2018 B2
10142496 Rao et al. Nov 2018 B1
10151928 Ushakov Dec 2018 B2
10154239 Casas Dec 2018 B2
10159530 Lang Dec 2018 B2
10163207 Merlet Dec 2018 B2
10166079 McLachlin et al. Jan 2019 B2
10175507 Nakamura Jan 2019 B2
10175753 Boesen Jan 2019 B2
10181361 Dillavou et al. Jan 2019 B2
10186055 Takahashi et al. Jan 2019 B2
10188672 Wagner Jan 2019 B2
10194131 Casas Jan 2019 B2
10194990 Amanatullah et al. Feb 2019 B2
10194993 Roger et al. Feb 2019 B2
10195076 Fateh Feb 2019 B2
10197803 Badiali et al. Feb 2019 B2
10197816 Waisman et al. Feb 2019 B2
10207315 Appleby et al. Feb 2019 B2
10212517 Beltran et al. Feb 2019 B1
10230719 Vaughn et al. Mar 2019 B2
10231893 Lei et al. Mar 2019 B2
10235606 Miao et al. Mar 2019 B2
10240769 Braganca et al. Mar 2019 B1
10247965 Ton Apr 2019 B2
10251724 McLachlin et al. Apr 2019 B2
10261324 Chuang et al. Apr 2019 B2
10262424 Ketcha et al. Apr 2019 B2
10274731 Maimone Apr 2019 B2
10278777 Lang May 2019 B1
10292768 Lang May 2019 B2
10296805 Yang et al. May 2019 B2
10319154 Chakravarthula et al. Jun 2019 B1
10326975 Casas Jun 2019 B2
10332267 Rai et al. Jun 2019 B2
10339719 Jagga et al. Jul 2019 B2
10352543 Braganca et al. Jul 2019 B1
10357146 Fiebel et al. Jul 2019 B2
10357574 Hilderbrand et al. Jul 2019 B2
10366489 Boettger et al. Jul 2019 B2
10368947 Lang Aug 2019 B2
10368948 Tripathi Aug 2019 B2
10382748 Benishti et al. Aug 2019 B2
10383654 Yilmaz et al. Aug 2019 B2
10386645 Abou Shousha Aug 2019 B2
10398514 Ryan et al. Sep 2019 B2
10405825 Rai et al. Sep 2019 B2
10405927 Lang Sep 2019 B1
10413752 Berlinger et al. Sep 2019 B2
10419655 Sivan Sep 2019 B2
10420626 Tokuda et al. Sep 2019 B2
10420813 Newell-Rogers et al. Sep 2019 B2
10424115 Ellerbrock Sep 2019 B2
D862469 Sadot et al. Oct 2019 S
10426554 Siewerdsen et al. Oct 2019 B2
10429675 Greget Oct 2019 B2
10431008 Djajadiningrat et al. Oct 2019 B2
10433814 Razzaque et al. Oct 2019 B2
10434335 Takahashi et al. Oct 2019 B2
10441236 Bar-Tal et al. Oct 2019 B2
10444514 Abou Shousha et al. Oct 2019 B2
10447947 Liu Oct 2019 B2
10448003 Grafenberg Oct 2019 B2
10449040 Lashinski et al. Oct 2019 B2
10453187 Peterson et al. Oct 2019 B2
10463434 Siegler et al. Nov 2019 B2
10465892 Feinbloom et al. Nov 2019 B1
10466487 Blum et al. Nov 2019 B2
10470732 Baumgart et al. Nov 2019 B2
10473314 Braganca et al. Nov 2019 B1
10485989 Jordan et al. Nov 2019 B2
10488663 Choi Nov 2019 B2
D869772 Gand Dec 2019 S
D870977 Berggren et al. Dec 2019 S
10492755 Lin et al. Dec 2019 B2
10499997 Weinstein et al. Dec 2019 B2
10502363 Edwards et al. Dec 2019 B2
10504231 Fiala Dec 2019 B2
10507066 Dimaio et al. Dec 2019 B2
10511822 Casas Dec 2019 B2
10517544 Taguchi et al. Dec 2019 B2
10537395 Perez Jan 2020 B2
10540780 Cousins et al. Jan 2020 B1
10543485 Ismagilov et al. Jan 2020 B2
10546423 Jones et al. Jan 2020 B2
10548557 Lim et al. Feb 2020 B2
10555775 Hoffman et al. Feb 2020 B2
10568535 Roberts et al. Feb 2020 B2
10571696 Urey et al. Feb 2020 B2
10571716 Chapiro Feb 2020 B2
10573087 Gallop et al. Feb 2020 B2
10577630 Zhang et al. Mar 2020 B2
10586400 Douglas Mar 2020 B2
10591737 Yildiz et al. Mar 2020 B2
10592748 Cousins et al. Mar 2020 B1
10594998 Casas Mar 2020 B1
10595716 Nazareth et al. Mar 2020 B2
10601950 Devam et al. Mar 2020 B2
10602114 Casas Mar 2020 B2
10603113 Lang Mar 2020 B2
10603133 Wang et al. Mar 2020 B2
10606085 Toyama Mar 2020 B2
10610172 Hummel et al. Apr 2020 B2
10610179 Altmann Apr 2020 B2
10613352 Knoll Apr 2020 B2
10617566 Esmonde Apr 2020 B2
10620460 Carabin Apr 2020 B2
10621738 Miao et al. Apr 2020 B2
10625099 Takahashi et al. Apr 2020 B2
10626473 Mariani et al. Apr 2020 B2
10631905 Asfora et al. Apr 2020 B2
10631907 Zucker et al. Apr 2020 B2
10634331 Feinbloom et al. Apr 2020 B1
10634921 Blum et al. Apr 2020 B2
10638080 Ovchinnikov et al. Apr 2020 B2
10646285 Siemionow et al. May 2020 B2
10650513 Penney et al. May 2020 B2
10650594 Jones et al. May 2020 B2
10652525 Woods May 2020 B2
10653495 Gregerson et al. May 2020 B2
10660715 Dozeman May 2020 B2
10663738 Carlvik et al. May 2020 B2
10672145 Albiol et al. Jun 2020 B2
10682112 Pizaine et al. Jun 2020 B2
10682767 Grafenberg et al. Jun 2020 B2
10687901 Thomas Jun 2020 B2
10691397 Clements Jun 2020 B1
10702713 Mori et al. Jul 2020 B2
10706540 Merlet Jul 2020 B2
10709398 Schweizer Jul 2020 B2
10713801 Jordan et al. Jul 2020 B2
10716643 Justin et al. Jul 2020 B2
10722733 Takahashi Jul 2020 B2
10725535 Yu Jul 2020 B2
10731832 Koo Aug 2020 B2
10732721 Clements Aug 2020 B1
10742949 Casas Aug 2020 B2
10743939 Lang Aug 2020 B1
10743943 Razeto et al. Aug 2020 B2
10747315 Tungare et al. Aug 2020 B2
10748319 Tao et al. Aug 2020 B1
10758315 Johnson et al. Sep 2020 B2
10777094 Rao et al. Sep 2020 B1
10777315 Zehavi et al. Sep 2020 B2
10781482 Gubatayao et al. Sep 2020 B2
10792110 Leung et al. Oct 2020 B2
10799145 West et al. Oct 2020 B2
10799296 Lang Oct 2020 B2
10799298 Crawford et al. Oct 2020 B2
10799316 Sela et al. Oct 2020 B2
10810799 Tepper et al. Oct 2020 B2
10818019 Piat et al. Oct 2020 B2
10818101 Gallop et al. Oct 2020 B2
10818199 Buras et al. Oct 2020 B2
10825563 Gibby et al. Nov 2020 B2
10831943 Santarone et al. Nov 2020 B2
10835296 Elimelech et al. Nov 2020 B2
10838206 Fortin-Deschnes et al. Nov 2020 B2
10839629 Jones et al. Nov 2020 B2
10839956 Beydoun et al. Nov 2020 B2
10841556 Casas Nov 2020 B2
10842002 Chang Nov 2020 B2
10842461 Johnson et al. Nov 2020 B2
10849691 Zucker et al. Dec 2020 B2
10849693 Lang Dec 2020 B2
10849710 Liu Dec 2020 B2
10861236 Geri et al. Dec 2020 B2
10865220 Ebetino et al. Dec 2020 B2
10869517 Halpern Dec 2020 B1
10869727 Yanof et al. Dec 2020 B2
10872472 Watola et al. Dec 2020 B2
10877262 Luxembourg Dec 2020 B1
10877296 Lindsey et al. Dec 2020 B2
10878639 Douglas et al. Dec 2020 B2
10893260 Trail et al. Jan 2021 B2
10895742 Schneider et al. Jan 2021 B2
10895743 Dausmann Jan 2021 B2
10895906 West et al. Jan 2021 B2
10898151 Harding et al. Jan 2021 B2
10921595 Rakshit et al. Feb 2021 B2
10921613 Gupta et al. Feb 2021 B2
10928321 Rawle Feb 2021 B2
10928638 Ninan et al. Feb 2021 B2
10929670 Troy et al. Feb 2021 B1
10935815 Castaeda Mar 2021 B1
10935816 Ban et al. Mar 2021 B2
10936537 Huston Mar 2021 B2
10939973 Dimaio et al. Mar 2021 B2
10939977 Messinger et al. Mar 2021 B2
10941933 Ferguson Mar 2021 B2
10946108 Zhang et al. Mar 2021 B2
10950338 Douglas Mar 2021 B2
10951872 Casas Mar 2021 B2
10964095 Douglas Mar 2021 B1
10964124 Douglas Mar 2021 B1
10966768 Poulos Apr 2021 B2
10993754 Kuntz et al. May 2021 B2
11000335 Dorman May 2021 B2
11006093 Hegyi May 2021 B1
11013550 Rioux et al. May 2021 B2
11013560 Lang May 2021 B2
11013562 Marti et al. May 2021 B2
11013573 Chang May 2021 B2
11013900 Malek et al. May 2021 B2
11019988 Fiebel et al. Jun 2021 B2
11027027 Manning et al. Jun 2021 B2
11029147 Abovitz et al. Jun 2021 B2
11030809 Wang Jun 2021 B2
11041173 Zhang et al. Jun 2021 B2
11045663 Mori et al. Jun 2021 B2
11049293 Chae et al. Jun 2021 B2
11049476 Fuchs et al. Jun 2021 B2
11050990 Casas Jun 2021 B2
11057505 Dharmatilleke Jul 2021 B2
11058390 Douglas Jul 2021 B1
11061257 Hakim Jul 2021 B1
11064904 Kay et al. Jul 2021 B2
11065062 Frushour et al. Jul 2021 B2
11067387 Marell et al. Jul 2021 B2
11071497 Hallack et al. Jul 2021 B2
11079596 Hua et al. Aug 2021 B2
11087039 Duff et al. Aug 2021 B2
11090019 Siemionow et al. Aug 2021 B2
11097129 Sakata et al. Aug 2021 B2
11099376 Steier et al. Aug 2021 B1
11103320 Leboeuf et al. Aug 2021 B2
D930162 Cremer et al. Sep 2021 S
11109762 Steier et al. Sep 2021 B1
11112611 Kessler et al. Sep 2021 B1
11122164 Gigante Sep 2021 B2
11123604 Fung Sep 2021 B2
11129562 Roberts et al. Sep 2021 B2
11132055 Jones et al. Sep 2021 B2
11135015 Crawford et al. Oct 2021 B2
11135016 Frielinghaus et al. Oct 2021 B2
11137610 Kessler et al. Oct 2021 B1
11141221 Hobeika et al. Oct 2021 B2
11153549 Casas Oct 2021 B2
11153555 Healy et al. Oct 2021 B1
11163176 Karafin et al. Nov 2021 B2
11164324 Liu et al. Nov 2021 B2
11166006 Hegyi Nov 2021 B2
11172990 Lang Nov 2021 B2
11179136 Kohli et al. Nov 2021 B2
11180557 Noelle Nov 2021 B2
11181747 Kessler et al. Nov 2021 B1
11185891 Cousins et al. Nov 2021 B2
11202682 Staunton et al. Dec 2021 B2
11207150 Healy et al. Dec 2021 B2
11217028 Jones et al. Jan 2022 B2
11224483 Steinberg et al. Jan 2022 B2
11224763 Takahashi et al. Jan 2022 B2
11227417 Berlinger et al. Jan 2022 B2
11231787 Isaacs et al. Jan 2022 B2
11244508 Kazanzides et al. Feb 2022 B2
11253216 Crawford et al. Feb 2022 B2
11253323 Hughes et al. Feb 2022 B2
11257190 Mao et al. Feb 2022 B2
11257241 Tao Feb 2022 B2
11263772 Siemionow et al. Mar 2022 B2
11269401 West et al. Mar 2022 B2
11272151 Casas Mar 2022 B2
11278359 Siemionow et al. Mar 2022 B2
11278413 Lang Mar 2022 B1
11280480 Wilt et al. Mar 2022 B2
11284846 Graumann et al. Mar 2022 B2
11291521 Im Apr 2022 B2
11294167 Ishimoda Apr 2022 B2
11297285 Pierce Apr 2022 B2
11300252 Nguyen Apr 2022 B2
11300790 Cheng et al. Apr 2022 B2
11304621 Merschon et al. Apr 2022 B2
11304759 Kovtun et al. Apr 2022 B2
11307402 Steier et al. Apr 2022 B2
11308663 Alhrishy et al. Apr 2022 B2
11311341 Lang Apr 2022 B2
11317973 Calloway et al. May 2022 B2
11337763 Choi May 2022 B2
11348257 Lang May 2022 B2
11350072 Quiles Casas May 2022 B1
11350965 Yilmaz et al. Jun 2022 B2
11351006 Aferzon et al. Jun 2022 B2
11354813 Piat et al. Jun 2022 B2
11360315 Tu et al. Jun 2022 B2
11382699 Wassall et al. Jul 2022 B2
11382700 Calloway et al. Jul 2022 B2
11382712 Elimelech et al. Jul 2022 B2
11382713 Healy et al. Jul 2022 B2
11389252 Gera et al. Jul 2022 B2
11399895 Soper et al. Aug 2022 B2
11402524 Song et al. Aug 2022 B2
11406338 Tolkowsky Aug 2022 B2
11423554 Borsdorf et al. Aug 2022 B2
11432828 Lang Sep 2022 B1
11432931 Lang Sep 2022 B2
11452568 Lang Sep 2022 B2
11460915 Frielinghaus et al. Oct 2022 B2
11461983 Jones et al. Oct 2022 B2
11464581 Calloway Oct 2022 B2
11478214 Siewerdsen et al. Oct 2022 B2
11483532 Quiles Casas Oct 2022 B2
11490986 BEn-Yishai Nov 2022 B2
11527002 Govari Dec 2022 B2
11528393 Garofolo et al. Dec 2022 B2
11627924 Alexandroni et al. Apr 2023 B2
11648016 Hathaway et al. May 2023 B2
11657518 Ketcha et al. May 2023 B2
11666458 Kim et al. Jun 2023 B2
11669984 Siewerdsen et al. Jun 2023 B2
11712582 Miyazaki et al. Aug 2023 B2
11750794 Benishti et al. Sep 2023 B2
11766296 Wolf et al. Sep 2023 B2
11798178 Merlet Oct 2023 B2
11801097 Crawford et al. Oct 2023 B2
11801115 Elimelech et al. Oct 2023 B2
11826111 Mahfouz Nov 2023 B2
11839501 Takahashi et al. Dec 2023 B2
11885752 St-Aubin et al. Jan 2024 B2
11896445 Gera et al. Feb 2024 B2
20020082498 Wendt et al. Jun 2002 A1
20030059097 Abovitz et al. Mar 2003 A1
20030117393 Sauer et al. Jun 2003 A1
20030130576 Seeley et al. Jul 2003 A1
20030156144 Morita Aug 2003 A1
20030210812 Khamene et al. Nov 2003 A1
20030225329 Rossner et al. Dec 2003 A1
20040019263 Jutras et al. Jan 2004 A1
20040030237 Lee et al. Feb 2004 A1
20040138556 Cosman Jul 2004 A1
20040238732 State et al. Dec 2004 A1
20050017972 Poole et al. Jan 2005 A1
20050024586 Teiwes et al. Feb 2005 A1
20050119639 McCombs et al. Jun 2005 A1
20050203367 Ahmed et al. Sep 2005 A1
20050203380 Sauer et al. Sep 2005 A1
20050215879 Chuanggui Sep 2005 A1
20060072124 Smetak et al. Apr 2006 A1
20060134198 Tawa et al. Jun 2006 A1
20060176242 Jaramaz et al. Aug 2006 A1
20070018975 Chuanggui et al. Jan 2007 A1
20070058261 Sugihara et al. Mar 2007 A1
20070183041 McCloy et al. Aug 2007 A1
20070233371 Stoschek et al. Oct 2007 A1
20070273610 Baillot Nov 2007 A1
20080002809 Bodduluri Jan 2008 A1
20080007645 McCutchen Jan 2008 A1
20080035266 Danziger Feb 2008 A1
20080085033 Haven et al. Apr 2008 A1
20080159612 Fu et al. Jul 2008 A1
20080183065 Goldbach Jul 2008 A1
20080221625 Hufner et al. Sep 2008 A1
20080253527 Boyden et al. Oct 2008 A1
20080262812 Arata et al. Oct 2008 A1
20080287728 Mostafavi et al. Nov 2008 A1
20090018437 Cooke Jan 2009 A1
20090024127 Lechner et al. Jan 2009 A1
20090036902 DiMaio et al. Feb 2009 A1
20090062869 Claverie et al. Mar 2009 A1
20090099445 Burger Apr 2009 A1
20090123452 Madison May 2009 A1
20090227847 Tepper et al. Sep 2009 A1
20090285366 Essenreiter et al. Nov 2009 A1
20090300540 Russell Dec 2009 A1
20100076305 Maier-Hein et al. Mar 2010 A1
20100094308 Tatsumi et al. Apr 2010 A1
20100106010 Rubner et al. Apr 2010 A1
20100114110 Taft et al. May 2010 A1
20100138939 Bentzon et al. Jun 2010 A1
20100149073 Chaum et al. Jun 2010 A1
20100172567 Prokoski Jul 2010 A1
20100210939 Hartmann et al. Aug 2010 A1
20100266220 Zagorchev et al. Oct 2010 A1
20100274124 Jascob et al. Oct 2010 A1
20110004259 Stallings et al. Jan 2011 A1
20110098553 Robbins et al. Apr 2011 A1
20110105895 Kornblau et al. May 2011 A1
20110216060 Weising et al. Sep 2011 A1
20110245625 Trovato et al. Oct 2011 A1
20110248064 Marczyk Oct 2011 A1
20110254922 Schaerer et al. Oct 2011 A1
20110306873 Shenai et al. Dec 2011 A1
20120014608 Watanabe Jan 2012 A1
20120068913 Bar-Zeev Mar 2012 A1
20120078236 Schoepp Mar 2012 A1
20120109151 Maier-Hein et al. May 2012 A1
20120143050 Heigl Jun 2012 A1
20120155064 Waters Jun 2012 A1
20120162452 Liu Jun 2012 A1
20120182605 Hall et al. Jul 2012 A1
20120201421 Hartmann et al. Aug 2012 A1
20120216411 Wevers et al. Aug 2012 A1
20120224260 Healy et al. Sep 2012 A1
20120238609 Srivastava et al. Sep 2012 A1
20120289777 Chopra et al. Nov 2012 A1
20120306850 Balan Dec 2012 A1
20120320100 Machida et al. Dec 2012 A1
20130002928 Imai Jan 2013 A1
20130009853 Hesselink et al. Jan 2013 A1
20130038632 Dillavou et al. Feb 2013 A1
20130050258 Liu et al. Feb 2013 A1
20130050833 Lewis et al. Feb 2013 A1
20130057581 Meier Mar 2013 A1
20130083009 Geisner et al. Apr 2013 A1
20130106833 Fun May 2013 A1
20130135734 Shafer et al. May 2013 A1
20130135738 Shafer et al. May 2013 A1
20130190602 Liao et al. Jul 2013 A1
20130195338 Xu et al. Aug 2013 A1
20130209953 Arlinsky et al. Aug 2013 A1
20130234914 Fujimaki Sep 2013 A1
20130234935 Griffith Sep 2013 A1
20130237811 Mihailescu et al. Sep 2013 A1
20130245461 Maier-Hein et al. Sep 2013 A1
20130249787 Morimoto Sep 2013 A1
20130249945 Kobayashi Sep 2013 A1
20130265623 Sugiyama et al. Oct 2013 A1
20130267838 Fronk Oct 2013 A1
20130278635 Maggiore Oct 2013 A1
20130300637 Smits et al. Nov 2013 A1
20130300760 Sugano et al. Nov 2013 A1
20130342571 Kinnebrew et al. Dec 2013 A1
20140031668 Mobasser et al. Jan 2014 A1
20140049629 Siewerdsen et al. Feb 2014 A1
20140088402 Xu Mar 2014 A1
20140088990 Nawana et al. Mar 2014 A1
20140104505 Koenig Apr 2014 A1
20140105912 Noelle Apr 2014 A1
20140114173 Bar-Tal et al. Apr 2014 A1
20140142426 Razzaque et al. May 2014 A1
20140168261 Margolis et al. Jun 2014 A1
20140176661 Smurro et al. Jun 2014 A1
20140177023 Gao et al. Jun 2014 A1
20140189508 Granchi et al. Jul 2014 A1
20140198129 Liu et al. Jul 2014 A1
20140218291 Kirk Aug 2014 A1
20140240484 Kodama et al. Aug 2014 A1
20140243614 Rothberg et al. Aug 2014 A1
20140256429 Kobayashi et al. Sep 2014 A1
20140266983 Christensen Sep 2014 A1
20140268356 Bolas et al. Sep 2014 A1
20140270505 McCarthy Sep 2014 A1
20140275760 Lee et al. Sep 2014 A1
20140285404 Takano et al. Sep 2014 A1
20140285429 Simmons Sep 2014 A1
20140300632 Laor Oct 2014 A1
20140300967 Tilleman et al. Oct 2014 A1
20140301624 Barckow et al. Oct 2014 A1
20140303491 Shekhar et al. Oct 2014 A1
20140320399 Kim et al. Oct 2014 A1
20140333899 Smithwick Nov 2014 A1
20140336461 Reiter et al. Nov 2014 A1
20140340286 Machida et al. Nov 2014 A1
20140361956 Mikhailov et al. Dec 2014 A1
20150005772 Anglin et al. Jan 2015 A1
20150018672 Blumhofer et al. Jan 2015 A1
20150031985 Reddy et al. Jan 2015 A1
20150043798 Carrell et al. Feb 2015 A1
20150070347 Hofmann et al. Mar 2015 A1
20150084990 Laor Mar 2015 A1
20150150641 Daon et al. Jun 2015 A1
20150182293 Yang et al. Jul 2015 A1
20150192776 Lee et al. Jul 2015 A1
20150209119 Theodore et al. Jul 2015 A1
20150261922 Nawana et al. Sep 2015 A1
20150277123 Chaum et al. Oct 2015 A1
20150282735 Rossner Oct 2015 A1
20150287188 Gazit et al. Oct 2015 A1
20150287236 Winne et al. Oct 2015 A1
20150297314 Fowler et al. Oct 2015 A1
20150305828 Park et al. Oct 2015 A1
20150310668 Ellerbrock Oct 2015 A1
20150338652 Lim et al. Nov 2015 A1
20150350517 Duret et al. Dec 2015 A1
20150351863 Plassky et al. Dec 2015 A1
20150363978 Maimone et al. Dec 2015 A1
20150366620 Cameron et al. Dec 2015 A1
20160022287 Nehls Jan 2016 A1
20160030131 Yang et al. Feb 2016 A1
20160054571 Tazbaz et al. Feb 2016 A1
20160086380 Vayser et al. Mar 2016 A1
20160103318 Du et al. Apr 2016 A1
20160125603 Tanji May 2016 A1
20160133051 Aonuma et al. May 2016 A1
20160143699 Tanji May 2016 A1
20160153004 Zhang et al. Jun 2016 A1
20160163045 Penney et al. Jun 2016 A1
20160175064 Steinle et al. Jun 2016 A1
20160178910 Giudicelli et al. Jun 2016 A1
20160191887 Casas Jun 2016 A1
20160223822 Harrison et al. Aug 2016 A1
20160228033 Rossner Aug 2016 A1
20160246059 Halpin et al. Aug 2016 A1
20160249989 Devam et al. Sep 2016 A1
20160256223 Haimerl et al. Sep 2016 A1
20160275684 Elenbaas et al. Sep 2016 A1
20160302870 Wilkinson et al. Oct 2016 A1
20160324580 Esterberg Nov 2016 A1
20160324583 Kheradpir et al. Nov 2016 A1
20160339337 Ellsworth et al. Nov 2016 A1
20170014119 Capote et al. Jan 2017 A1
20170024634 Miao et al. Jan 2017 A1
20170027650 Merck et al. Feb 2017 A1
20170031163 Gao et al. Feb 2017 A1
20170031179 Guillot et al. Feb 2017 A1
20170045742 Greenhalgh et al. Feb 2017 A1
20170068119 Antaki et al. Mar 2017 A1
20170076501 Jagga et al. Mar 2017 A1
20170086941 Marti et al. Mar 2017 A1
20170112586 Dhupar Apr 2017 A1
20170164919 Lavallee et al. Jun 2017 A1
20170164920 Lavallee et al. Jun 2017 A1
20170178375 Benishti et al. Jun 2017 A1
20170220224 Kodali et al. Aug 2017 A1
20170239015 Sela et al. Aug 2017 A1
20170245944 Crawford et al. Aug 2017 A1
20170251900 Hansen et al. Sep 2017 A1
20170252109 Yang et al. Sep 2017 A1
20170258526 Lang Sep 2017 A1
20170281283 Siegler et al. Oct 2017 A1
20170312032 Amanatullah et al. Nov 2017 A1
20170348055 Salcedo et al. Dec 2017 A1
20170348061 Joshi et al. Dec 2017 A1
20170366773 Kiraly et al. Dec 2017 A1
20170367766 Mahfouz Dec 2017 A1
20170367771 Tako et al. Dec 2017 A1
20170372477 Penney et al. Dec 2017 A1
20180003981 Urey Jan 2018 A1
20180018791 Guoyi Jan 2018 A1
20180021597 Berlinger et al. Jan 2018 A1
20180028266 Barnes et al. Feb 2018 A1
20180036884 Chen et al. Feb 2018 A1
20180049622 Ryan et al. Feb 2018 A1
20180055579 Daon et al. Mar 2018 A1
20180078316 Schaewe et al. Mar 2018 A1
20180082480 White et al. Mar 2018 A1
20180092667 Heigl et al. Apr 2018 A1
20180092698 Chopra et al. Apr 2018 A1
20180092699 Finley Apr 2018 A1
20180116732 Lin et al. May 2018 A1
20180117150 O'Dwyer et al. May 2018 A1
20180133871 Farmer May 2018 A1
20180153626 Yang et al. Jun 2018 A1
20180182150 Benishti et al. Jun 2018 A1
20180185100 Weinstein et al. Jul 2018 A1
20180185113 Gregerson et al. Jul 2018 A1
20180193097 McLachlin et al. Jul 2018 A1
20180200002 Kostrzewski et al. Jul 2018 A1
20180247128 Alvi et al. Aug 2018 A1
20180262743 Casas Sep 2018 A1
20180303558 Thomas Oct 2018 A1
20180311011 Van et al. Nov 2018 A1
20180317803 Ben-Yishai et al. Nov 2018 A1
20180318035 McLachlin et al. Nov 2018 A1
20180368898 Divincenzo et al. Dec 2018 A1
20190000372 Gullotti et al. Jan 2019 A1
20190000564 Navab et al. Jan 2019 A1
20190015163 Abhari et al. Jan 2019 A1
20190018235 Ouderkirk et al. Jan 2019 A1
20190038362 Nash et al. Feb 2019 A1
20190038365 Soper et al. Feb 2019 A1
20190043238 Benishti et al. Feb 2019 A1
20190043392 Abele Feb 2019 A1
20190046272 Zoabi et al. Feb 2019 A1
20190046276 Inglese et al. Feb 2019 A1
20190053851 Siemionow et al. Feb 2019 A1
20190069971 Tripathi et al. Mar 2019 A1
20190080515 Geri et al. Mar 2019 A1
20190105116 Johnson et al. Apr 2019 A1
20190130792 Rios et al. May 2019 A1
20190142519 Siemionow et al. May 2019 A1
20190144443 Jackson et al. May 2019 A1
20190175228 Elimelech et al. Jun 2019 A1
20190192230 Siemionow et al. Jun 2019 A1
20190200894 Jung et al. Jul 2019 A1
20190201106 Siemionow et al. Jul 2019 A1
20190216537 Eltorai et al. Jul 2019 A1
20190254753 Johnson et al. Aug 2019 A1
20190273916 Benishti et al. Sep 2019 A1
20190310481 Blum et al. Oct 2019 A1
20190333480 Lang Oct 2019 A1
20190369660 Wen et al. Dec 2019 A1
20190369717 Frielinghaus et al. Dec 2019 A1
20190387351 Lyren et al. Dec 2019 A1
20200015895 Frielinghaus et al. Jan 2020 A1
20200019364 Pond Jan 2020 A1
20200020249 Jarc et al. Jan 2020 A1
20200038112 Amanatullah et al. Feb 2020 A1
20200043160 Mizukura et al. Feb 2020 A1
20200078100 Weinstein et al. Mar 2020 A1
20200085511 Oezbek et al. Mar 2020 A1
20200088997 Lee et al. Mar 2020 A1
20200100847 Siegler et al. Apr 2020 A1
20200117025 Sauer Apr 2020 A1
20200129058 Li et al. Apr 2020 A1
20200129136 Harding et al. Apr 2020 A1
20200129262 Verard et al. Apr 2020 A1
20200129264 Oativia et al. Apr 2020 A1
20200133029 Yonezawa Apr 2020 A1
20200138518 Lang May 2020 A1
20200138618 Roszkowiak et al. May 2020 A1
20200143594 Lal et al. May 2020 A1
20200146546 Chene et al. May 2020 A1
20200151507 Siemionow et al. May 2020 A1
20200156259 Ruiz et al. May 2020 A1
20200159313 Gibby et al. May 2020 A1
20200163723 Wolf et al. May 2020 A1
20200163739 Messinger et al. May 2020 A1
20200178916 Lalys et al. Jun 2020 A1
20200184638 Meglan et al. Jun 2020 A1
20200186786 Gibby et al. Jun 2020 A1
20200188028 Feiner et al. Jun 2020 A1
20200188034 Lequette et al. Jun 2020 A1
20200201082 Carabin Jun 2020 A1
20200229877 Siemionow et al. Jul 2020 A1
20200237256 Farshad et al. Jul 2020 A1
20200237459 Racheli et al. Jul 2020 A1
20200237880 Kent et al. Jul 2020 A1
20200242280 Pavloff et al. Jul 2020 A1
20200246074 Lang Aug 2020 A1
20200246081 Johnson et al. Aug 2020 A1
20200264451 Blum et al. Aug 2020 A1
20200265273 Wei et al. Aug 2020 A1
20200275988 Johnson et al. Sep 2020 A1
20200281554 Trini et al. Sep 2020 A1
20200286222 Essenreiter et al. Sep 2020 A1
20200288075 Bonin et al. Sep 2020 A1
20200294233 Merlet Sep 2020 A1
20200297427 Cameron et al. Sep 2020 A1
20200305980 Lang Oct 2020 A1
20200315734 El Amm Oct 2020 A1
20200321099 Holladay et al. Oct 2020 A1
20200323460 Busza et al. Oct 2020 A1
20200323609 Johnson et al. Oct 2020 A1
20200327721 Siemionow et al. Oct 2020 A1
20200330179 Ton Oct 2020 A1
20200337780 Winkler et al. Oct 2020 A1
20200341283 McCracken et al. Oct 2020 A1
20200352655 Freese Nov 2020 A1
20200355927 Marcellin-Dibon et al. Nov 2020 A1
20200360091 Murray et al. Nov 2020 A1
20200375666 Murphy Dec 2020 A1
20200377493 Heiser et al. Dec 2020 A1
20200377956 Vogelstein et al. Dec 2020 A1
20200388075 Kazanzides et al. Dec 2020 A1
20200389425 Bhatia et al. Dec 2020 A1
20200390502 Holthuizen et al. Dec 2020 A1
20200390503 Casas et al. Dec 2020 A1
20200402647 Domracheva et al. Dec 2020 A1
20200409306 Gelman et al. Dec 2020 A1
20200410687 Siemionow et al. Dec 2020 A1
20200413031 Khani et al. Dec 2020 A1
20210004956 Book et al. Jan 2021 A1
20210009339 Morrison et al. Jan 2021 A1
20210015560 Boddington et al. Jan 2021 A1
20210015583 Avisar et al. Jan 2021 A1
20210022599 Freeman et al. Jan 2021 A1
20210022808 Lang Jan 2021 A1
20210022811 Mahfouz Jan 2021 A1
20210022828 Elimelech et al. Jan 2021 A1
20210029804 Chang Jan 2021 A1
20210030374 Takahashi et al. Feb 2021 A1
20210030511 Wolf et al. Feb 2021 A1
20210038339 Yu et al. Feb 2021 A1
20210049825 Wheelwright et al. Feb 2021 A1
20210052348 Stifter et al. Feb 2021 A1
20210065911 Goel et al. Mar 2021 A1
20210077195 Saeidi et al. Mar 2021 A1
20210077210 Itkowitz et al. Mar 2021 A1
20210080751 Lindsey et al. Mar 2021 A1
20210090344 Geri et al. Mar 2021 A1
20210093391 Poltaretskyi et al. Apr 2021 A1
20210093392 Poltaretskyi et al. Apr 2021 A1
20210093400 Quaid et al. Apr 2021 A1
20210093417 Liu Apr 2021 A1
20210104055 Ni et al. Apr 2021 A1
20210107923 Jackson et al. Apr 2021 A1
20210109349 Schneider et al. Apr 2021 A1
20210109373 Loo et al. Apr 2021 A1
20210110517 Flohr et al. Apr 2021 A1
20210113269 Vilsmeier et al. Apr 2021 A1
20210113293 Silva et al. Apr 2021 A9
20210121238 Palushi et al. Apr 2021 A1
20210137634 Lang May 2021 A1
20210141887 Kim et al. May 2021 A1
20210150702 Claessen et al. May 2021 A1
20210157544 Denton May 2021 A1
20210160472 Casas May 2021 A1
20210161614 Elimelech et al. Jun 2021 A1
20210162287 Xing et al. Jun 2021 A1
20210165207 Peyman Jun 2021 A1
20210169504 Brown Jun 2021 A1
20210169578 Calloway et al. Jun 2021 A1
20210169581 Calloway et al. Jun 2021 A1
20210169605 Calloway et al. Jun 2021 A1
20210186647 Elimelech et al. Jun 2021 A1
20210196404 Wang Jul 2021 A1
20210211640 Bristol et al. Jul 2021 A1
20210223577 Zhang et al. Jul 2021 A1
20210227791 De et al. Jul 2021 A1
20210235061 Hegyi Jul 2021 A1
20210248822 Choi et al. Aug 2021 A1
20210274281 Zhang et al. Sep 2021 A1
20210278675 Klug et al. Sep 2021 A1
20210282887 Wiggermann Sep 2021 A1
20210290046 Nazareth et al. Sep 2021 A1
20210290336 Wang Sep 2021 A1
20210290394 Mahfouz Sep 2021 A1
20210295512 Knoplioch et al. Sep 2021 A1
20210298835 Wang Sep 2021 A1
20210306599 Pierce Sep 2021 A1
20210311322 Belanger et al. Oct 2021 A1
20210314502 Liu Oct 2021 A1
20210315636 Akbarian et al. Oct 2021 A1
20210315662 Freeman et al. Oct 2021 A1
20210325684 Ninan et al. Oct 2021 A1
20210332447 Lubelski et al. Oct 2021 A1
20210333561 Oh et al. Oct 2021 A1
20210341739 Cakmakci et al. Nov 2021 A1
20210341740 Cakmakci et al. Nov 2021 A1
20210346115 Dulin et al. Nov 2021 A1
20210349677 Baldev et al. Nov 2021 A1
20210369226 Siemionow et al. Dec 2021 A1
20210371413 Thurston et al. Dec 2021 A1
20210373333 Moon Dec 2021 A1
20210373344 Loyola et al. Dec 2021 A1
20210378757 Bay et al. Dec 2021 A1
20210386482 Gera et al. Dec 2021 A1
20210389590 Freeman et al. Dec 2021 A1
20210400247 Casas Dec 2021 A1
20210401533 Im Dec 2021 A1
20210402255 Fung Dec 2021 A1
20210405369 King Dec 2021 A1
20220003992 Ahn Jan 2022 A1
20220007006 Healy et al. Jan 2022 A1
20220008135 Frielinghaus et al. Jan 2022 A1
20220038675 Hegyi Feb 2022 A1
20220039873 Harris Feb 2022 A1
20220051484 Jones et al. Feb 2022 A1
20220054199 Sivaprakasam et al. Feb 2022 A1
20220061921 Crawford et al. Mar 2022 A1
20220071712 Wolf et al. Mar 2022 A1
20220079675 Lang Mar 2022 A1
20220087746 Lang Mar 2022 A1
20220113810 Isaacs et al. Apr 2022 A1
20220117669 Nikou et al. Apr 2022 A1
20220121041 Hakim Apr 2022 A1
20220133484 Lang May 2022 A1
20220142730 Wolf et al. May 2022 A1
20220155861 Myung et al. May 2022 A1
20220159227 Quiles Casas May 2022 A1
20220179209 Cherukuri Jun 2022 A1
20220192776 Gibby et al. Jun 2022 A1
20220193453 Miyazaki et al. Jun 2022 A1
20220201274 Achilefu et al. Jun 2022 A1
20220245400 Siemionow et al. Aug 2022 A1
20220245821 Ouzounis Aug 2022 A1
20220269077 Adema et al. Aug 2022 A1
20220270263 Junio Aug 2022 A1
20220287676 Steines et al. Sep 2022 A1
20220292786 Pelzl et al. Sep 2022 A1
20220295033 Quiles Casas Sep 2022 A1
20220304768 Elimelech et al. Sep 2022 A1
20220351385 Finley et al. Nov 2022 A1
20220358759 Cork et al. Nov 2022 A1
20220392085 Finley et al. Dec 2022 A1
20220405935 Flossmann et al. Dec 2022 A1
20230009793 Gera et al. Jan 2023 A1
20230027801 Qian et al. Jan 2023 A1
20230034189 Gera et al. Feb 2023 A1
20230073041 Samadani et al. Mar 2023 A1
20230149083 Lin et al. May 2023 A1
20230290037 Tasse et al. Sep 2023 A1
20230295302 Bhagavatheeswaran et al. Sep 2023 A1
20230316550 Hiasa Oct 2023 A1
20230329799 Gera et al. Oct 2023 A1
20230329801 Elimelech et al. Oct 2023 A1
20230371984 Leuthardt et al. Nov 2023 A1
20230372053 Elimelech et al. Nov 2023 A1
20230372054 Elimelech et al. Nov 2023 A1
20230377175 Seok Nov 2023 A1
20230379449 Benishti et al. Nov 2023 A1
20230386153 Ltd Nov 2023 A1
20230397349 Capelli et al. Dec 2023 A1
20230397957 Crawford et al. Dec 2023 A1
20230410445 Elimelech et al. Dec 2023 A1
20240008935 Wolf et al. Jan 2024 A1
20240016549 Johnson et al. Jan 2024 A1
20240016572 Elimelech et al. Jan 2024 A1
20240020831 Johnson et al. Jan 2024 A1
20240020840 Johnson et al. Jan 2024 A1
20240020862 Johnson et al. Jan 2024 A1
20240022704 Benishti et al. Jan 2024 A1
20240023946 Wolf et al. Jan 2024 A1
20240041558 Siewerdsen et al. Feb 2024 A1
Foreign Referenced Citations (116)
Number Date Country
3022448 Feb 2018 CA
3034314 Feb 2018 CA
101379412 Mar 2009 CN
103106348 May 2013 CN
111915696 Nov 2020 CN
112489047 Mar 2021 CN
202004011567 Nov 2004 DE
102004011567 Sep 2005 DE
102014008153 Oct 2014 DE
0933096 Aug 1999 EP
1640750 Mar 2006 EP
1757974 Feb 2007 EP
2134847 Dec 2009 EP
2868277 May 2015 EP
2891966 Jul 2015 EP
3034607 Jun 2016 EP
3076660 Oct 2016 EP
3123970 Feb 2017 EP
2654749 May 2017 EP
3216416 Sep 2017 EP
2032039 Oct 2017 EP
3224376 Oct 2017 EP
3247297 Nov 2017 EP
3306567 Apr 2018 EP
2030193 Jul 2018 EP
2892558 Apr 2019 EP
2635299 Jul 2019 EP
3505050 Jul 2019 EP
2875149 Dec 2019 EP
3593227 Jan 2020 EP
3634294 Apr 2020 EP
3206583 Sep 2020 EP
2625845 Mar 2021 EP
3789965 Mar 2021 EP
3858280 Aug 2021 EP
3913423 Nov 2021 EP
3952331 Feb 2022 EP
4287120 Dec 2023 EP
2507314 Apr 2014 GB
10-2014-0120155 Oct 2014 KR
0334705 Apr 2003 WO
2006002559 Jan 2006 WO
2007051304 May 2007 WO
2007115826 Oct 2007 WO
2008103383 Aug 2008 WO
2010067267 Jun 2010 WO
2010074747 Jul 2010 WO
2012061537 May 2012 WO
2012101286 Aug 2012 WO
2013112554 Aug 2013 WO
2014014498 Jan 2014 WO
2014024188 Feb 2014 WO
2014037953 Mar 2014 WO
2014113455 Jul 2014 WO
2014125789 Aug 2014 WO
2014167563 Oct 2014 WO
2014174067 Oct 2014 WO
2015058816 Apr 2015 WO
2015061752 Apr 2015 WO
2015109145 Jul 2015 WO
2016151506 Sep 2016 WO
2018052966 Mar 2018 WO
2018073452 Apr 2018 WO
2018200767 Nov 2018 WO
2018206086 Nov 2018 WO
2019083431 May 2019 WO
2019135209 Jul 2019 WO
2019161477 Aug 2019 WO
2019195926 Oct 2019 WO
2019210353 Nov 2019 WO
2019211741 Nov 2019 WO
2020109903 Jun 2020 WO
2020109904 Jun 2020 WO
2021017019 Feb 2021 WO
2021019369 Feb 2021 WO
2021021979 Feb 2021 WO
2021023574 Feb 2021 WO
2021046455 Mar 2021 WO
2021048158 Mar 2021 WO
2021061459 Apr 2021 WO
2021062375 Apr 2021 WO
2021073743 Apr 2021 WO
2021087439 May 2021 WO
2021091980 May 2021 WO
2021112918 Jun 2021 WO
2021130564 Jul 2021 WO
2021137752 Jul 2021 WO
2021141887 Jul 2021 WO
2021145584 Jul 2021 WO
2021154076 Aug 2021 WO
2021183318 Sep 2021 WO
2021188757 Sep 2021 WO
2021255627 Dec 2021 WO
2021257897 Dec 2021 WO
2021258078 Dec 2021 WO
2022009233 Jan 2022 WO
2022053923 Mar 2022 WO
2022079565 Apr 2022 WO
2023281395 Jan 2023 WO
2023007418 Feb 2023 WO
2023011924 Feb 2023 WO
2023021448 Feb 2023 WO
2023021450 Feb 2023 WO
2023021451 Feb 2023 WO
2023026229 Mar 2023 WO
2023047355 Mar 2023 WO
2023072887 May 2023 WO
2023088986 May 2023 WO
2023163933 Aug 2023 WO
2023186996 Oct 2023 WO
2023205212 Oct 2023 WO
2023209014 Nov 2023 WO
2023232492 Dec 2023 WO
2023240912 Dec 2023 WO
2024013642 Jan 2024 WO
2024018368 Jan 2024 WO
Non-Patent Literature Citations (63)
Entry
U.S. Appl. No. 15/896,102 (U.S. Pat. No. 10,134,166), filed Feb. 14, 2018 (Nov. 20, 2018), Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 16/159,740 (U.S. Pat. No. 10,382,748), filed Oct. 15, 2018 (Aug. 13, 2019), Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 16/419,023 (U.S. Pat. No. 11,750,794), filed May 22, 2019, Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 15/127,423 (U.S. Pat. No. 9,928,629), filed Sep. 20, 2016 (Mar. 27, 2018), Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 16/120,480 (U.S. Pat. No. 10,835,296), filed Sep. 4, 2018 (Nov. 17, 2020), Spinous Process Clamp.
U.S. Appl. No. 17/045,766, filed Oct. 7, 2020, Registration of a Fiducial Marker for an Augmented Reality System.
U.S. Appl. No. 16/199,281 (U.S. Pat. No. 10,939,977), filed Nov. 26, 2018 (Mar. 9, 2021), Positioning Marker.
U.S. Appl. No. 16/724,297 (U.S. Pat. No. 11,382,712), filed Dec. 22, 2019 (Jul. 12, 2022), Mirroring in Image Guided Surgery.
U.S. Appl. No. 16/901,026 (U.S. Pat. No. 11,389,252), filed Jun. 15, 2020 (Jul. 19, 2022), Rotating Marker for Image Guided Surgery.
U.S. Appl. No. 35/508,942 (U.S. Pat. No. D. 930,162), filed Feb. 13, 2020, (Sep. 7, 2021), Medical Headset.
International Search Report and Written Opinion received for PCT Patent Application No. PCT/IB2016/051642, dated Jul. 10, 2016, 6 pages.
IPEA/409—International Preliminary Report on Patentability dated Oct. 5, 2017 for WO Application No. PCT/IB16/051642, 5 page(s).
U.S. Appl. No. 15/896,102, filed Feb. 14, 2018, Combining Video-Based and Optic-Based Augmented Reality in a Near Rye Display.
U.S. Appl. No. 16/159,740, filed Oct. 15, 2018, Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 16/419,023, filed May 22, 2019, Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 18/352,158, filed Jul. 13, 2023, Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 18/365,643, filed Aug. 4, 2023, Head-Mounted Augmented Reality Near Eye Display Device.
U.S. Appl. No. 18/365,650, filed Aug. 4, 2023, Systems for Facilitating Augmented Reality-Assisted Medical Procedures.
U.S. Appl. No. 15/127,423, filed Sep. 20, 2016, Combining Video-Based and Optic-Based Augmented Reality in a Near Eye Display.
U.S. Appl. No. 16/120,480, filed Sep. 4, 2018, Spinous Process Clamp.
U.S. Appl. No. 17/067,831, filed Oct. 12, 2020, Spinous Process Clamp.
U.S. Appl. No. 18/030,072, filed Apr. 4, 2023, Spinous Process Clamp.
U.S. Appl. No. 18/365,590, filed Aug. 4, 2023, Registration of a Fiducial Marker for an Augmented Reality System.
U.S. Appl. No. 18/365,571, filed Aug. 4, 2023, Registration Marker for an Augmented Reality System.
U.S. Appl. No. 18/632,588, filed Apr. 11, 2024, Registration of a Fudicial Marker for an Augmented Reality System.
U.S. Appl. No. 17/045,766, filed Oct. 7, 2020, Registration of a Fudicial Marker for an Augmented Reality System.
U.S. Appl. No. 16/199,281, filed Nov. 26, 2018, Positioning Marker.
U.S. Appl. No. 16/524,258, filed Jul. 29, 2019, Fiducial Marker.
U.S. Appl. No. 17/585,629, filed Jan. 27, 2022, Fiducial Marker.
U.S. Appl. No. 18/631,804, filed Apr. 10, 2024, Fiducial Marker.
U.S. Appl. No. 16/724,297, filed Dec. 22, 2019, Mirroring in Image Guided Surgery.
U.S. Appl. No. 17/827,710, filed May 29, 2022, Mirroring in Image Guided Surgery.
U.S. Appl. No. 18/352,181, filed Jul. 13, 2023, Mirroring in Image Guided Surgery.
U.S. Appl. No. 18/400,739, filed Dec. 29, 2023, Mirroring in Image Guided Surgery.
U.S. Appl. No. 16/200,144, filed Nov. 26, 2018, Tracking System for Image-Guided Surgery.
U.S. Appl. No. 18/470,809, filed Sep. 20, 2023, Tracking Methods for Image-Guided Surgery.
U.S. Appl. No. 18/631,877, filed Apr. 10, 2024, Tracking Systems and for Methods for Image-Guided Surgery.
U.S. Appl. No. 17/015,199, filed Sep. 9, 2020, Universal Tool Adapter.
U.S. Appl. No. 18/598,965, filed Mar. 7, 2024, Universal Tool Adapter for Image Guided Surgery.
U.S. Appl. No. 18/044,380, filed Mar. 8, 2023, Universal Tool Adapter for Image-Guided Surgery.
U.S. Appl. No. 16/901,026, filed Jun. 15, 2020, Rotating Marker for Image Guided Surgery.
U.S. Appl. No. 18/008,980, filed Dec. 8, 2022, Rotating Marker.
U.S. Appl. No. 17/368,859, filed Jul. 7, 2021, Iliac Pin and Adapter.
U.S. Appl. No. 18/437,898, filed Feb. 9, 2024, Iliac Pin and Adapter.
U.S. Appl. No. 18/576,516, filed Jan. 4, 2024, Iliac Pin and Adapter.
U.S. Appl. No. 17/388,064, filed Jul. 29, 2021, Rotating Marker and Adapter for Image-Guided Surgery.
U.S. Appl. No. 18/291,731, filed Jan. 24, 2024, Rotating Marker and Adapter for Image-Guided Surgery.
U.S. Appl. No. 18/365,844, filed Aug. 4, 2023, Augmented-Reality Surgical System Using Depth Sensing.
U.S. Appl. No. 18/683,676, filed Feb. 14, 2024, Stereoscopic Display and Digital Loupe for Augmented-Reality Near-Eye Display.
U.S. Appl. No. 18/683,680, filed Feb. 14, 2024, Augmented Reality Assistance for Osteotomy and Discectomy.
U.S. Appl. No. 18/684,756, filed Feb. 19, 2024, Registration and Registration Validation in Image-Guided Surgery.
U.S. Appl. No. 18/693,338, filed Mar. 19, 2024, Surgical Planning and Display.
U.S. Appl. No. 18/365,566, filed Aug. 4, 2023, Systems for Medical Image Visualization.
U.S. Appl. No. 18/399,523, filed Dec. 28, 2023, Methods for Medical Image Visualization.
U.S. Appl. No. 18/398,837, filed Dec. 28, 2023, Adjustable Augmented Reality Eyewear for Image-Guided Medical Intervention.
U.S. Appl. No. 18/399,433, filed Dec. 28, 2023, Configurable Augmented Reality Eyewear for Image-Guided Medical Intervention.
U.S. Appl. No. 35/508,942, filed Feb. 13, 2020, Medical Headset.
16 Augmented Reality Glasses of 2021 (with Features), in Back to News, Dated May 6, 2022, accessed at https://web.archive.org/web/20221127195438/https://circuitstream.com/blog/16-augmented-reality-glasses-of-2021-with-features-breakdowns/.
Everysight, Installing your RX Adaptor, accessed Mar. 13, 2024 at https://support.everysight.com/hc/en-US/articles/115000984571-Installing-your-RX-Adaptor.
Everysight, Raptor User Manual, copyright 2017, in 46 pages.
Frames Direct, InSpatialRx Prescription Insert, Prescription Insert for Magic Leap 1, accessed Mar. 8, 2024 at https://www.framesdirect.com/inspatialrx-prescription-insert. html.
Reddit, Notice on Prescription Lenses for Nreal Glasses, accessed Mar. 13, 2024 at https://www.reddit.com/r/nreal/comments/x1fte5/notice_on_prescription_lenses_for_nreal_glasses/.
Vuzix Blades, Prescription Lens Installation Guide, copyright 2020.
Related Publications (1)
Number Date Country
20230379448 A1 Nov 2023 US
Continuations (4)
Number Date Country
Parent 16419023 May 2019 US
Child 18365643 US
Parent 16159740 Oct 2018 US
Child 16419023 US
Parent 15896102 Feb 2018 US
Child 16159740 US
Parent 15127423 US
Child 15896102 US